Hydrochlorothiazide - Blood Pressure, Elpradil

Blood Pressure - Elpradil hct (Brand name: hydrochlorothiazide)

Hydrochlorothiazide is used for treating high blood pressure. It is also used to treat fluid buildup in the body caused by certain conditions (e. g. heart failure, liver cirrhosis, kidney problems) or medicines (e. g. corticosteroids, estrogen). It may be used alone or with other medicines. It may also be used for other conditions as determined by your doctor.

Use Hydrochlorothiazide as directed by your doctor.

Take Hydrochlorothiazide by mouth with or without food. Hydrochlorothiazide may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm. Ask your health care provider any questions you may have about how to use Hydrochlorothiazide. Drug Class and Mechanism

Hydrochlorothiazide is a thiazide diuretic. It helps the kidneys to remove fluid from the body.

If you miss a dose of Hydrochlorothiazide and are using it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Store Hydrochlorothiazide between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Hydrochlorothiazide out of the reach of children and away from pets.

Do not use Hydrochlorothiazide if:

you are allergic to any ingredient in Hydrochlorothiazide; you are unable to urinate; you are taking dofetilide or ketanserin. Contact your doctor or health care provider right away if any of these apply to you.

Important : Hydrochlorothiazide may cause dizziness or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Hydrochlorothiazide with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it. Hydrochlorothiazide may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects. Your doctor may also prescribe a potassium supplement for you. If so, take the potassium supplement exactly as prescribed. Do not start taking additional potassium on your own or change your diet to include more potassium without first checking with your doctor. Tell your doctor or dentist that you take Hydrochlorothiazide before you receive any medical or dental care, emergency care, or surgery. Tell your doctor if you will be exposed to high temperatures. The risk of certain side effects (eg, low blood sodium levels) may be increased in hot weather. Hydrochlorothiazide may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Hydrochlorothiazide. Use a sunscreen or wear protective clothing if you must be outside for more than a short time. Hydrochlorothiazide may raise your blood sugar. High blood sugar may make you feel confused, drowsy, or thirsty. It can also make you flush, breathe faster, or have a fruit-like breath odor. If these symptoms occur, tell your doctor right away. Diabetes patients - Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine. Lab tests, including kidney function, blood pressure, and electrolyte levels, may be performed while you use Hydrochlorothiazide. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments. Pregnancy and breast-feeding: Hydrochlorothiazide may cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Hydrochlorothiazide while you are pregnant. Hydrochlorothiazide is found in breast milk. If you are or will be breast-feeding while you use Hydrochlorothiazide, check with your doctor. Discuss any possible risks to your baby.

Possible Side Effects

Check with your doctor if any of these most common side effects persist or become bothersome:

Constipation; diarrhea; dizziness; lightheadedness (especially when sitting up or standing); loss of appetite; nausea; temporary blurred vision. Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dark urine; decreased urination; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; increased thirst; joint pain, swelling, warmth, or redness (especially of the big toe joint); mental or mood changes; muscle pain or cramps; numbness or tingling; red, swollen, blistered, or peeling skin; seizures; severe or persistent dizziness; severe or persistent nausea or stomach pain; shortness of breath; unusual bruising or bleeding; unusual drowsiness, restlessness, tiredness, or weakness; unusually dry mouth; vomiting; yellowing of the eyes or skin.

If you have any questions about Hydrochlorothiazide, please talk with your doctor, pharmacist, or other health care provider. Hydrochlorothiazide is to be used only by the patient for whom it is prescribed. Do not share it with other people.

Bijsluiter Van Geneesmiddelen Propymal, Propymal

Depakine® Orfiril® Natriumvalproaat Tabletten/ Drank (generiek)

Capsules, maagsapbestendig (= maagsapresistent): 150 mg, 300 mg, 450 mg of 600 mg valproinezuur Drank: 300 mg valproinezuur per 5 ml

Apotex Europe BV

Toepassingen (= indicaties) o. a.

Epilepsie migraine Algemeen Lees ook de patientenbijsluiter voor informatie over de toepassing van dit medicijn.

Gebruikt u dit geneesmiddel en bent u zwanger of wilt u zwanger worden? In het Universitair Medisch Centrum Utrecht wordt onderzoek gedaan naar: - gebruik van dit geneesmiddel tijdens de zwangerschap - de effecten van dit geneesmiddel op het ongeboren kind Uw medewerking hieraan is van groot belang! Meer informatie: www. eurap. nl

Niet gebruiken bij (= contra-indicaties) o. a.

Alvleesklierfunctie-stoornissen Bloedingsneiging, verhoogde (hemorragische diathese) Leverfunctie-stoornissen Leverfunctie-stoornissen t. g.v. gebruik van dit medicijn of vergelijkbare middelen (= valproaten), ook indien in de familie voorgekomen Overgevoeligheid of allergie voor dit medicijn of vergelijkbare middelen Algemeen Breng ook een vervangende arts of een medisch specialist op de hoogte van eventuele andere ziekten of klachten die u heeft. Hiermee kunt u voorkomendat u verkeerde medicijnen krijgt voorgeschreven. Lees ook de bijsluiter in de verpakking om te zien wanneer dit medicijn niet mag worden gebruikt.

Dit middel kan schadelijk zijn tijdens de zwangerschap. Dit medicijn niet gebruiken tijdens de zwangerschap (tenzij de arts anders voorschrijft). Borstvoeding

Tijdens gebruik van dit middel geen borstvoeding geven De werkzame stof gaat over in de moedermelk. Algemeen Sommige medicijnen kunnen een schadelijke invloed hebben op het verloop van de zwangerschap, de nog ongeboren vrucht (= foetus) of de pasgeboren zuigeling (= neonatus). Van veel medicijnen is dat echter nog niet precies bekend. Veel medicijnen komen in de moedermelk terecht en bereiken zo de baby. Gebruik daarom tijdens zwangerschap of borstvoeding alleen medicijnen op doktersvoorschrift . Vertel ook een vervangende arts of een medisch specialist als u van plan bent zwanger te worden, zwanger bent of borstvoeding geeft. Hiermee kunt u voorkomendat u medicijnen krijgt voorgeschreven, die niet mogen worden gebruikt tijdens zwangerschap of borstvoeding. Raadpleeg altijd eerst uw arts wanneer u van plan bent tijdens zwangerschap of periode van borstvoeding oude medicijnen. zelfzorgmedicijnen of alternatieve middelen te gaan gebruiken. Lees ook de patientenbijsluiter voor informatie over het gebruik van dit medicijn tijdens zwangerschap of borstvoeding.

Verkeer, werk en sport

Dit medicijn kan als mogelijke bijwerkingen - vooral in combinatie met andere medicijnen tegen epilepsie - duizeligheid en/of slaperigheid veroorzaken. Hiervan kunnen allerlei dagelijkse activiteiten, zoals bezigheden in en rond het huis, deelname aan het verkeer, het bedienen of besturen van machines en sporten ernstige hinder ondervinden. Algemeen Lees ook de patientenbijsluiter voor informatie over de invloed van dit medicijn op het reactie-, concentratie - en/of gezichtsvermogen.

Dit medicijn is werkzaam tegen epilepsie (= anti-epileptische werking). Dit medicijn kan een migraine aanval voorkomen. Algemeen Lees ook de patientenbijsluiter voor informatie over de werking van dit middel.

Mogelijke bijwerkingen (o. a.)

Bevingen (= tremoren) Bewegingscoordinatie-stoornissen (= ataxie) Bloedingstijd, verlengde Braken, vooral in het begin Diarree, vooral in het begin Eetlust, toename Leverbeschadigingen, vooral bij kinderen en soms zeer ernstig Lusteloosheid Maagdarm-klachten, vooral in het begin Maagkrampen, vooral in het begin Misselijkheid, vooral in het begin Slaperigheid (= somnolentie) Sufheid (= sedatie), vooral in het begin Algemeen De bijwerkingen staan vermeld in de bijsluiter in de verpakking. Vaak is er maar een kleine kans op bijwerkingen. Er zijn echter ook geneesmiddelen met een betrekkelijk grote kans op bijwerkingen. De kans op bijwerkingen wordt gewoonlijk groter bij hogere doseringen . Wanneer tijdens het gebruik van dit medicijn effecten optreden die u niet kent, verwacht of vreemd vindt, kan dat wijzen op: (1) een bijwerking van dit medicijn, (2) wisselwerking van dit medicijn met een ander medicijn of voedsel of op (3) overgevoeligheid voor dit medicijn of (4) een allergische reactie op dit medicijn. Het is mogelijk dat u overgevoelig of allergisch bent (of wordt) voor een bepaald medicijn. Als u weet dat u overgevoelig of allergisch bent voor een bepaald medicijn, moet u dat medicijn niet gebruiken. Vergeet echter niet uw arts te vertellen voor welk(e) middel(en) u overgevoelig bent. Zo voorkomt u dat u dat medicijn nogmaals voorgeschreven krijgt. Breng ook een vervangende arts of medisch specialist op de hoogte van overgevoeligheid of allergie voor bepaalde medicijnen. Als een medicijn al wat langer op de markt is, worden er niet zelden nieuwe bijwerkingen ontdekt. Hierdoor neemt het aantal 'bekende' bijwerkingen van een medicijn soms met de jaren toe. Een al wat ouder medicijn met veel bijwerkingen is daarom niet per se onveiliger dan een nieuw medicijn, waarvan dikwijls nog maar weinig bijwerkingen opgemerkt en aangemeld zijn bij de daarvoor verantwoordelijke instantie. Lees de patientenbijsluiter voor meer informatie over de mogelijke bijwerkingen van dit medicijn.

Mogelijke wisselwerkingen (= interacties) o. a.

Acetylsalicylzuur (o. a. Aspirine®) Antidepressiva Antipsychotica Barbituraten Bloedstolling-vertragende middelen (= 'trombose middelen', anticoagulantia) Carbamazepine (= Carbymal®, Tegretol®) Fenobarbital Fenytoine (= Diphantoine®, Epanutin®) Primidon (= Mysoline®) Algemeen Vertel ook een vervangende huisarts of medisch specialist welke medicijnen u gebruikt. Zo kunt u voorkomendat u medicijnen krijgt voorgeschreven, die niet mogen worden gecombineerd met medicijnen die u al gebruikt. Lees ook de patientenbijsluiter voor informatie over mogelijke wisselwerkingen van dit medicijn met andere medicijnen, met voedsel of met drank.

Zie etiket en de gebruiksaanwijzing inde bijsluiter. De capsules voor of tijdens de maaltijd zonder kauwen heel innemen. Algemeen Vraag uw arts of apotheker om uitleg als u niet goed begrijpt hoe u dit medicijn moet gebruiken. Doe dat ook als u dat niet meer precies weet of wanneer u dat bent vergeten.

In de verpakking bij kamertemperatuur. Algemeen Kleine kinderen denken vaak dat medicijnen eetbaar, drinkbaar of snoepgoed zijn. Bewaar medicijnen daarom altijd buiten bereik van kleine kinderen. De meeste medicijnen zijn in de originele verpakking goed houdbaar bij kamertemperatuur (lees ook het bewaarvoorschrift in de bijsluiter). Bewaar medicijnen nooit in een warme en/of vochtige omgeving. zoals bijvoorbeeld douchecel of badkamer. De uiterste gebruiksdatum van een medicijn staat vermeld op de verpakking. Overtollige medicijnen niet bewaren, aan anderen geven of in vuilnisbak of toilet gooien. U kunt ze het beste terugbrengen naar de apotheek. Lees ook de patientenbijsluiter voor informatie over de houdbaarheid en de wijze van bewaren van dit middel.

Correct gebruik van medicijnen

In de praktijk wordt 50% van alle medicijnen niet, onvoldoende of verkeerd gebruikt! Het gebruik van medicijnen heeft echter alleen zin wanneer ze correct worden gebruikt. Dat wil zeggen nauwkeurig volgens het voorschrift van de arts. Wanneer u te weinig van dit medicijn gebruikt (= onderdosering), werkt het niet of onvoldoende, zodat de klachten niet over gaan of steeds weer terugkeren. Gebruik daarom niet minder dan de voorgeschreven hoeveelheid. Wanneer u te veel van dit medicijn gebruikt (= overdosering), kan dat leiden tot ongewenste bijwerkingen en zelfs tot ziekenhuisopname. Gebruik daarom niet m‚‚r dan de voorgeschreven hoeveelheid. Vraag uw arts of apotheker om uitleg als u niet precies (meer) weet hoe u uw medicijnen moet gebruiken of wanneer u dat bent vergeten. Zelf combineren van medicijnen

U moet zelf nooit medicijnen, die de dokter heeft voorgeschreven, combineren met zelfzorg-medicijnen. Dat kan leiden tot ongewenste wisselwerkingen (= interacties) en zelfs tot ziekenhuisopname. Vraag altijd eerst advies aan uw arts of apotheker als u naast dit medicijn ook nog zelfzorg-medicijnen wilt gebruiken. Vertrouwen in de medicijnen

Voor een goed resultaat is het van groot belang dat u vertrouwen in uw medicijnen heeft. Wanneer u denkt dat u het verkeerde medicijn heeft gekregen, bang bent voor bijwerkingen of denkt dat de medicijnen die u heeft gekregen niet helpen, kan dat uw vertrouwen in de medicijnen ernstig ondermijnen. In de praktijk is gebleken dat geneesmiddelen dan vaak slecht worden gebruikt (= medicatie-ontrouw). Bespreek eventuele problemen aangaande uw medicijnen altijd met uw arts of apotheker. Deze kunnen dan uw ongerustheid wegnemen of bekijken of u misschien een andere dosering of andere medicijnen nodig heeft.

Epilepsie-patienten moeten hun medicijnen altijd innemen om nieuwe epilepsie-aanvallen te voork¢men. Dit omdat tijdens een aanval de kans op een ongeluk groter is en omdat iedere nieuwe aanval de ziekte verergert. In de praktijk betekent dit dat epilepsie-patienten hun medicijnen levenslang zeer trouw moeten gebruiken. Gebruik op eigen initiatief niet meer of minder geneesmiddel dan is voorgeschreven door de dokter. Bespreek uw ervaringen en eventuele problemen met dit medicijn regelmatig met uw (huis)arts. Vertel hem/haar ook of u wel of niet tevreden bent over het voorgeschreven medicijn. Als dat niet het geval is, kan worden bekeken of de dosis moet worden aangepast of dat u een ander medicijn nodig heeft. Bespreek voorafgaande aan een (voorgenomen) zwangerschap met uw (huis)arts of u dit medicijn dan nog mag gebruiken of dat u over moet stappen op en ander medicijn tegen uw epilepsie. Als u niet (meer) weet hoe u dit middel moet gebruiken of problemen met het gebruik heeft, moet u dat beslist voorleggen aan uw arts of apotheker.

Dit medicijn is alleen op doktersrecept verkrijgbaar en wordt daarom vergoed volgens de daarvoor geldende regels van de overheid en uw zorgverzekeraar . Er zijn ook geneesmiddelen die alleen op recept verkrijgbaar zijn (= UR-geneesmiddelen), maar slechts ten dele of niet vergoed worden. Vraag uw arts, apotheker of zorgverzekeraar zo nodig om nadere informatie over de vergoeding van uw medicijnen.

Bijsluiter bij Propymal® Algemeen U kunt uw arts of apotheker zo nodig om meer informatie over dit middel vragen.

Mogelijke verschijnselen na overdosering (o. a.)

Slaperigheid die kan overgaan in bewusteloosheid (= coma). Algemeen Blijf kalm en neem telefonisch contact op met de (huis)arts of het dichtst bijzijnde ziekenhuis wanneer sprake is van overdosering of wanneer overdosering wordt vermoed. Hou de bijsluiter of verpakking van het betreffende medicijn bij de hand als u naar een (huis)arts, poli of ziekenhuis gaat. Lees ook de bijsluiter in de verpakking over mogelijke verschijnselen en wijze van handelen bij overdosering.

Khasiat Klebet, Klabet

Biji tanaman bernama klabet mungkin bagi sebagian orang masih asing. Padahal, biji tanaman yang biasa dimanfaatkan untuk bumbu masakan Timur Tengah ini mempunyai banyak manfaat. Tidak banyak orang yang pernah mendengar nama Klabet, padahal biji tanaman ini sudah dipakai sebagai salah satu rempah dalam berbagai jenis masakan, terutama masakan yang berasal dan Timur Tengah. Untuk membuat gulai kambing misalnya. biji klabet diramu bersama cengkeh, kayu manis, kapulaga, serai yang ditumbuk halus. Sementara itu, yang perlu diperhatikan adalah penggunaan biji klabet dalam berbagai komposisi jamu Indonesia. Banyak ramuan jamu, terutama yang berasal dan P. Jawa, menggunakan klabet sebagai salah satu bahan. Selain jamu yang diminum, ada pula ramuan untuk berendam yang memasukkan klabet sebagai salah satu bahan. bahkan sebagai obat luar untuk luka. Banyak penelitian ilmiah yang dilakukan terhadap klabet, dan hasilnya memang menjanjikan. Barangkali faktor inilah yang menyebabkan biji klabet dipakai dalam ramuan jamu Jawa.

Khasiat Klabet populer dengan sebutan fe nugreek dalam bahasa lnggris. Tanaman asalnya bernama ilmiah Trigo nella foenum graecum dan suku Legu minosae. Tanaman ini tumbuh subur dan luas di kawasan India, Mesir dan negara Timur Tengah. Bagian yang dipakai terutama adalah biji yang bentuknya tidak beraturan dan berwana kuning muda. Di India, biji klabet terkenal dengan sebutan methi dan dipakai sebagai bumbu masak. Biji ini juga dipakai dalam sistem pengobatan Ayurveda dari India, yaitu yang dipercayai dapat menimbulkan efek penurun kadar kolesterol darah pada binatang percobaan. Pemakaian dalam sistem pengobatan tradisional India, China, Arab yang luas adalah sebagai obat diabetes dan hiperkolesterol. Khasiat lain yang tercatat adalah untuk mengatasi gangguan saluran cerna, seperti kembung, batuk, bronchitis, tenggorokan sakit, panas badan yang meningkat dan sariawan pada rongga mulut. Orang India juga mencampur biji klabet dan yoghurt yang digunakan sebagai hair conditioner. Saat ini banyak penelitian ilmiah yang sudah dilakukan untuk membuktikan khasiat untuk mengobati diabetes pada hewan percobaan. Hasilnya memang menunjukkan terdapatnya potensi itu walaupun tentu saja masih harus melalui pembuiktian secara lebih lanjut. Aktivitas anti radang ekstrak biji klabet pada tikus juga sudah dilaporkan.

Kandungan Biji klabet mengandung karbohidrat sampai 60 persen, protein, minyak lemak. minyak atsiri, flavonoid, saponin dan kumarin. Ada hasil peneiltian yang menunjukkan bahwa khasiat menurunkan kadar gula darah di tunjukkan oleh kerja senyawa alkaloid tri-gonelline dan juga kumarin. Yang menarik ada peneliti yang berhasil mengisolasi senyawa diosgenin, yaitu yang merupakan bahan baku utama dalam produksi hormon steroid untuk program keluarga berencana.

Meningkatkan ASI Khasiat biji klabet untuk melancarkan pengeluaran air susu ibu menarik sekali untuk dipelajari. Sejak tahun 1945, seorang peneliti Mesir melaporkan hasil penelitian yang membuktikan bahwa kiabet berkhasiat sebagai stimulator kuat bagi produksi air susu Ibu. Hingga kini belum diketahui mekanisme kerjanya, dan oleh sebab itu pemakaian untuk tujuan itu dianjurkan. Hal ini terutama karena diketahui bahwa klabet relatif aman bagi bayi yang sedang menyusui. Efek samping yang mungkin terjadi adalah diare, dan kalau itu terjadi maka dianjurkan untuk menurunkan dosis pemakaian. Peneliti itu juga menganjurkan agar di samping mengonsumsi klabet, ibu juga harus rajin menyusui atau memompa air susunya.

Antikanker Kanker mernang masih menjadi pembunuh manusia nomor dua di seluruh dunia. Pengobatan dengan sistem modern berpeluang menimbulkan efek samping yang makin memperburuk kondisi kesehatan umum penderita. Oleh sebab itu, dari waktu ke waktu terjadi peningkatan kebutuhan akan sistem pengobatan alternatif untuk mencegah dan menyembuhkan kanker. Khasiat ekstrak biji klabet untuk antikanker telah mengundang minat peneliti, dimana hasilnya ternyata menggembirakan. Pada penelitian laboratorium yang menggunakan human acute T Lymphoblastic leukemia cell lines, diperoleh hasil bahwa telah terjadi penghambatan pertumbuhan sel, kematian sel dan perubahan morfologi sel. Hasil ini memang mendukung efek antikanker biji klabet terhadap cell line tersebut.

Dosis dan Cara Pemakaian Klabet merupakan terna tahunan, tumbuh tegak, tinggi 30 cm sampai 60 cm. Daun berbentuk bundar telur terbalik sampai bentuk baji. Bunga tunggal atau sepasang, keluar di ketiak daun, mahkota berwarna kuning terang. Buah polong gundul, memanjang atau berbentuk lanset. Buah berisi 10 sampai 20 biji.

Di pasaran kita bisa membeli biji klabet yang kering. Karena rasa dan bau yang mungkin kurang disukai, biji itu dapat digerus menjadi serbuk untuk pemakaiannya. Serbuk itu dapat juga kita masukkan ke dalam kapsul. Dosis pemakaian berkisar antara 1- 6 g untuk tiga kali pemakaian dalam sehari. Biji klabet juga dapat kita minum sebagai teh, yaitu dengan cara merebusnya untuk selanjutnya langsung disajikan air rebusannya. Orang Mesir gemar minum teh klabet, terutama pada musim dingin. Bagi pemula, disarankan untuk mengonsumsi dalam dosis minimal dan selanjutnya ditingkatkan sedikit demi sedikit. Hingga sekarang tidak ditemukan efek samping yang signifikan akibat konsumsi klabet, namun ibu hamil tidak dianjurkan untuk mengonsumsinya.

Hub. 0878 38 778700

Colinacol, Colinacol

Chloramphenicol

Click for further information on drug naming conventions and International Nonproprietary Names .

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Salora International Share Price, Nse, Salora

Stock Price Quotes

Salora International Ltd.

Salora International Ltd.

23 Aug,2016, 01:34PM IST

Salora International Ltd has informed BSE that the 47th Annual General Meeting (AGM) of the Company will be held on September 14, 2016.

Salora International Ltd has informed BSE that the 47th Annual General Meeting (AGM) of the Company will be held on September 14, 2016.less

Fixes Book Closure for AGM | Announcement

22 Aug,2016, 03:42PM IST

Salora International Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 08, 2016 to September 14, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 14, 2016.

Salora International Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 08, 2016 to September 14, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 14, 2016.less

Standalone Financial Results, Limited Review Report for June 30, 2016 | Announcement

12 Aug,2016, 03:07PM IST

Salora International Ltd has informed BSE about. 1. Standalone Financial Results for the period ended June 30, 2016 2. Standalone Limited Review for the period ended June 30, 2016

Salora International Ltd has informed BSE about. 1. Standalone Financial Results for the period ended June 30, 2016 2. Standalone Limited Review for the period ended June 30, 2016less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016 | Announcement

15 Jul,2016, 12:42AM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Outcome of Board Meeting | Announcement

30 Jun,2016, 03:57PM IST

Salora International Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2016, has been appointed Mrs. Neetu Jiwarajka as Additional Director (Executive) on the Board of the Company pursuant to provisions of the Companies Act, 2013 r. w. relevant rules made. more

Salora International Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2016, has been appointed Mrs. Neetu Jiwarajka as Additional Director (Executive) on the Board of the Company pursuant to provisions of the Companies Act, 2013 r. w. relevant rules made thereunder and Regulation 17 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.less

Shareholding for the Period Ended December 31, 2015 | Announcement

02 Feb,2016, 01:08PM IST

Salora International Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here

Salora International Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here less

Board Intimation for Results & Closure of Trading Window | Announcement

28 Jan,2016, 10:13AM IST

Salora International Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 11, 2016, inter alia, to consider and taken on record Unaudited Financial Results (Provisional) for 3rd Quarter ended December 31, 2015. Further, the trading window of the C. more

Salora International Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 11, 2016, inter alia, to consider and taken on record Unaudited Financial Results (Provisional) for 3rd Quarter ended December 31, 2015. Further, the trading window of the Company, in accordance with the "Salora International Limited - Code of Conduct" under SEBI (Prohibition of Insider Trading) Regulations, 2015, will be closed from February 01, 2016 to February 13, 2016 (both days inclusive). Therefore, all the Directors, Employees and Auditors including their immediate relatives are not permitted to deal in the shares of the Company till February 13, 2016.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 | Announcement

13 Jan,2016, 05:21PM IST

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salora International Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.less

Updates of Outcome of AGM | Announcement

29 Sep,2015, 06:20PM IST

Salora International Ltd has submitted to BSE a copy of the Minutes of 46th Annual General Meeting of the Company held on September 18, 2015.

Salora International Ltd has submitted to BSE a copy of the Minutes of 46th Annual General Meeting of the Company held on September 18, 2015.less

Scrutinizer Report on Postal Ballot | Announcement

28 Sep,2015, 07:14PM IST

Salora International Ltd has submitted to BSE a copy of Report of Scrutinizer on Postal Ballot dated September 26, 2015.

Salora International Ltd has submitted to BSE a copy of Report of Scrutinizer on Postal Ballot dated September 26, 2015.less

Salora International Ltd. incorporated in the year 1968, is a Mid Cap company (having a market cap of Rs 51.21 Cr.) operating in Consumer Durables sector.

Salora International Ltd. key Products/Revenue Segments include Mobile Phones & Accessories which contributed Rs 227.22 Cr to Sales Value (76.14% of Total Sales), Others which contributed Rs 59.78 Cr to Sales Value (20.03% of Total Sales), Other Sales which contributed Rs 59.78 Cr to Sales Value (20.03% of Total Sales), Sale of services which contributed Rs 7.74 Cr to Sales Value (2.59% of Total Sales), Wind Energy which contributed Rs 3.68 Cr to Sales Value (1.23% of Total Sales), Wind Energy which contributed Rs 3.68 Cr to Sales Value (1.23% of Total Sales), for the year ending 31-Mar-2015.

For the quarter ended 30-Jun-2016, the company has reported a Standalone sales of Rs. 97.08 Cr. up 23.33% from last quarter Sales of Rs. 78.71 Cr. and up 44.46% from last year same quarter Sales of Rs. 67.20 Cr. Company has reported net profit after tax of Rs. 0.11 Cr. in latest quarter.

The company’s management includes Mr. Nitin Agrahari, Mr. Nitin Agrahari, Mr. Gautam Khaitan, Mr. Gopal Sitaram Jiwarajka, Mr. K S Mehta, Mr. Patanjali Govind Keswani, Mr. Sanjeev Kaul Duggal, Mr. Tarun Jiwarajka, Mrs. Neetu Jiwarajka.

Company has K Prasad & Co. as its auditors. As on 30-Jun-2016, the company has a total of 8,807,300 shares outstanding.

Quick Links

Corex Ltd, Ucorex

Welcome to Corex

Corex Ltd. are manufacturers of large, tracked mineral processing equipment, boasting economically friendly high output production with low fuel consumption figures. Our machines, manufactured in Northern Ireland, require minimal setup and little to no preparation of material before processing.

Designed with you in mind Corex machines are built with a focus on simplicity. We know that in this industry in particular any time wasted is money wasted, which is why our machines are easy to transport, easy to setup, easy to operate and easy to adjust. We’ve proven that large processing machinery doesn’t have to sacrifice portability. The ‘flat-pack’ style design features of a Corex machine means that anyone, anywhere can have a high output portable crusher unit.

Fuel Efficient = Cost Efficient High productivity is usually paired with an exaggerated price and then a high running cost. Corex believe that every investment should be attractive, which is why when you buy a Corex machine your investment keeps on giving long after the sale. With worldwide oil prices forever increasing, our machines benefit from a fuel saving system that see a reduction in consumption by up to 50%.

'The more you put in, the more you get out. ' At Corex we’re so confident of our high output machinery that we made it our slogan. If you keep feeding the machine then it will keep crushing and keep producing your material at the other end. Our direct driven crushers means there is minimal power loss to the crushing unit itself, which not only helps in terms of productivity but will also dramatically reduce fuel consumption.

Meloxitor, Meloxitor

Meloxitor

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Elizabeth Kavaler, M, Kavelor

I have dedicated my career to the study and treatment of female urological disorders, such as chronic urinary tract infections, various kinds of incontinence, pelvic floor prolapse, and interstitial cystitis.

Traditionally, urology has been a specialty primarily populated by men, with a focus on male problems. I am determined to inform women that their problems are not only real, but treatable. Incontinence, pelvic pain and pelvic floor prolapse. all of these conditions are treatable, manageable or curable.

Women no longer need to be embarrassed or afflicted with bladder problems. Nobody has to suffer. Everyone can be helped, no matter how young or how old.

- Elizabeth Kavaler, M. D.

Listen to the nationally broadcast interview with Dr Kavaler on Peoplespharmacy. com on May 3rd, 2008.

Listen to Dr. Kavaler's latest interview with Donna Hanover on WOR-AM on August 2, 2007! Your browser does not support the audio element.

"A Seat On The Aisle, Please!"

In this concise, clearly written, and sympathetic new book, Dr. Elizabeth Kavaler suggests that a new approach to female urinary tract disorders is long overdue. One of the surprisingly small number of women practicing urology in the U. S. she explains what these diseases are and what patients can do to get properly diagnosed and appropriately treated. In addition, Dr. Kavaler extends compassionate, expert, and helpful advice to those who have been distressed, embarrassed, and isolated for too long.

Dexart, Dexart

Dexart's Profile

I’m freelance composer working mostly in cinematic genre. In my Portfolio you can find epic, hybrid, inspirational, fantasy, corporate, and piano music for your projects.

Also I provide custom music for your projects.

I’m available for work on different types of projects – films, games, trailers, commercial, etc. Don’t hesitate to contact me.

Also it would be interesting to see where you use my music, so feel free to share your works with me

P. S. If you have any questions or requests, just write me using contact form on Audiojungle. Thanks for stopping by

Public Collections

Epic&Hybrid

Featured Item

87 Followers

Nancy Joseph describes the DXARTS course 'Art and the Brain' in her article published in August 2016 UW Perspectives Newsletter. “There are a lot of. Learn more »

Juan Pampin's Percussion Cycle . recorded by Les Percussions de Strasbourg, released on CD by Sargasso Records

Juan Pampin’s Percussion Cycle for percussion instruments and electronic sounds, performed by the renowned Les Percussions de Strasbourg, is. Learn more »

UW Perspectives magazine has featured DXARTS Ph. D. student Marcin Paczkowski in the article by Nancy Joseph "A Marriage of Music and Motion". "In. Learn more »

Dexart's Profile

I’m freelance composer working mostly in cinematic genre. In my Portfolio you can find epic, hybrid, inspirational, fantasy, corporate, and piano music for your projects.

Also I provide custom music for your projects.

I’m available for work on different types of projects – films, games, trailers, commercial, etc. Don’t hesitate to contact me.

Also it would be interesting to see where you use my music, so feel free to share your works with me

P. S. If you have any questions or requests, just write me using contact form on Audiojungle. Thanks for stopping by

Public Collections

Epic&Hybrid

Featured Item

87 Followers

Sacrificial Anode Line Cutter Assembly, Salca

SALCA

SALCA was created to answer two of boaters' major problems in one effective and affordable product. It combines a sacrificial anode with a stainless steel disc line cutting blade, thereby offering both corrosion and entanglement protection simultaneously. It has successfully been put through a battery of tests to meet all the demands of meticulous boaters.

The SALCA Difference

SALCA is particularly useful for limited clearance areas, where there may not be enough space to install separate anode and line cutter. SALCA can compliment your traditional line cutter and give additional cutting protection

SALCA works as a sacrificial anode, naturally eroding while protecting the expensive metal components of your boat. Upon reaching approximately 50% of its original size, the entire unit should be replaced with a new SALCA providing continued corrosion control with a new line cutting blade.

Convenience, Strength, Affordability

SALCA is much more affordable than your traditional line cutter, but does not sacrifice durability for savings. It has been proven to endure several tons of pressure without separating the blade from the anode. The anode also provides corrosion protection to the stainless steel line cutter blade. SALCA installation is a simple process that can be carried out by you, your mechanic or your diver. SALCA can be installed on either side of the strut, with the blade facing the bearing. It can also be installed at the aft of the boat's strut between the prop and strut or cutless bearing.

Retin A Cream, Retirides

Retin A: An Anti-Aging Cream To Treat Acne and Wrinkles

Retin-A cream contains Tretinoin which is a form of Vitamin A. The Tretinoin active ingredient has been clinically proven to reverse the signs of aging by reducing wrinkles, removing fine lines and improving both the condition and appearance of the skin.

Retin-A cream is supplied in concentrations of 0.05%, 0.025% and 0.1%, each strength being tailored to a particular skin problem.

What Does Retin A Cream Do?

Thanks to its tretinoin ingredient, Retin-A cream is especially powerful in combating the visible signs of aging such as wrinkles and fine lines. Tests have shown that within just six weeks of usage, Retin-A 0.05% can help to reduce the number of wrinkles and make fine lines disappear.

The 0.025% cream is used for general skin improvement and the 0.1% Retin-A cream, the strongest concentration of the treatment and is widely used for acne. This is because in studies Tretinoin when applied topically decreased the formation of blackheads.

Aside from its use for acne and wrinkles, Retin A / Tretinoin has also been successfully used to reduce the appearance of stretch marks after pregnancy and by cosmetic surgeons to speed their patients recovery after surgery.

At antiaging-systems. com we also stock the latest micro-gel version of Retin-A. The micro gel technology allows the skin to absorb small amount of tretinoin over time and it remains on top of the skin and can therefore be washed off if required. Retin-A micro gel has been shown to be more effective than the standard Retin-A creams and is far less prone to side effects. In addition Retin-A micro gel reduces the appearance of oiliness or facial shine on the skin’s surface.

How Does Retin-A Cream Work?

Tretinoin (sometimes referred to as ATRA or ‘All-Trans Retinoic Acid’) improves the blood supply and increases the turnover of dead skin cells. The effects of the topical application of Tretinoin (i. e. massaging Tretinoin into the skin) have been well researched, particularly with regard to the photoaging of the skin. Overwhelming clinical evidence and the anatomical study of the microscopic structure of skin tissues indicates that topical retinoids such as Retin-A can reverse certain structural changes caused by excessive sun exposure. The Australasian College of Dermatologists estimate that chronic sun exposure or photoaging is probably responsible for over 90% of the visible signs of aging in Australians!

No wonder so many expensive skin products rave about the miniscule amounts of Tretinoin that they contain.

Retin A Skin Cream an Anti-Aging Treatment in Just Six Weeks

Retin-A is proven to be an effective antiaging product for rejuvenating skin and reducing the visible signs of aging, demonstrating remarkable changes in skin elasticity and firmness in just six weeks. Even in this short period, the results can be quite astonishing - fine lines can completely disappear, severe wrinkles can be greatly reduced and the skin can regain a youthful glow.

These benefits ensure that Retin A wrinkles and fine lines remover is a viable part of any beauty regime.

Articles

Sapox, Sapox

Sapox. jp

Countable Data Brief

Sapox. jp is tracked by us since May, 2015. Over the time it has been ranked as high as 590 999 in the world, while most of its traffic comes from Japan, where it reached as high as 32 307 position. All this time it was owned by Mediaflag Inc. . it was hosted by Amazon Technologies Inc. . Amazon. com Inc. and others.

Sapox has the lowest Google pagerank and bad results in terms of Yandex topical citation index. We found that Sapox. jp is poorly ‘socialized’ in respect to any social network. According to Siteadvisor and Google safe browsing analytics, Sapox. jp is quite a safe domain with no visitor reviews.

Worldwide Audience

Sapox. jp gets 100% of its traffic from Japan where it is ranked #78879.

Traffic Analysis

Sapox. jp has 343 visitors and 2.75K pageviews daily.

Subdomains Traffic Shares

Sapox. jp has no subdomains with considerable traffic.

SEO Stats

Sapox. jp is not yet effective in its SEO tactics: it has Google PR 0. It may also be penalized or lacking valuable inbound links.

Fusidic Acid, Betasid

Fusidic Acid

Click for further information on drug naming conventions and International Nonproprietary Names .

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Enadura Questions We Have Answers At Healthsofa, Enadura

Enadura is used to treat patients with high blood pressure. However, it should be used in combination to other medications. It is grouped under a class of medications called angiotensin converting enzyme (ACE) inhibitors, and works by eradicating some chemicals that stiffen the blood vessels, so that the blood is circulated to all parts easily. It is used to treat kidney diseases concerning diabetes.

Recent Forum Posts

Side Effects

nausea / constipation / chest pain / dizziness / headache / vomiting / cough / abdominal pain / drowsiness / insomnia / diarrhea / dyspepsia / dyspnea / bradycardia / anorexia / fatigue / nervousness / hypertension / hypertension / urinary tract infection / rash / weakness / fever / paresthesia / diaphoresis / hypotension / urticaria / pruritus / bronchitis / bronchospasm / alopecia / pulmonary edema / angina / palpitation /

Pregnancy

Pregnancy and Enadura Embryo and Enadura Fetal Weaning and Enadura Breastfeeding and Enadura

Dosage

How to Properly Take enalapril? What is the children dosage for Enadura What is the adult dosage for Enadura How often should Enadura be taken? What is the dosage for Enadura?

Usage

This medication is being used for: hypertension /

Storage

Paduden Onomatopoeia - Outdoor Advert By Tempo Advertising, Paduden

Credits & Description

Category: Cosmetics & Beauty, Toiletries & Pharmacy Advertiser: TERAPIA RANBAXY Product/Service: PADUDEN PAIN RELIEF Agency: TEMPO ADVERTISING Date of First Appearance: Apr 15 2011 Entrant Company: TEMPO ADVERTISING, Bucharest, ROMANIA Creative Director: Alexandru Pomana Copywriter: Alexandru Tigoianu Art Director: Dan Costea Account Manager: Irina Trifu Other Credits: Alexandru Icodin

The Outdoor Advert titled ONOMATOPOEIA was done by Tempo Advertising advertising agency for product: Paduden (brand: Terapia Ranbaxy) in Romania. It was released in Apr 2011.

Latest Terapia Ranbaxy Ads

ONOMATOPOEIA

Terapia Ranbaxy Tempo Advertising April 2011

Paduden: Ah-Ha

Terapia Ranbaxy Tempo Advertising April 2011

CHEMISTRY OF CONCENTRATION

Terapia Ranbaxy R K Swamy BBDO Mumbai March 2011

NO SUNDAYS

Terapia Ranbaxy R K Swamy BBDO Mumbai December 2009

EMBARRASSING STORIES

Terapia Ranbaxy denifednu January 2008

SHOCKS WITHOUT PALPITATIONS

Terapia Ranbaxy Propaganda April 2007

Latest Tempo Advertising Works

World Vision: 1000 Children

World Vision Tempo Advertising September 2011

World Vision 1000 Children

World Vision Tempo Advertising July 2011

1000 CHILDREN

World Vision Tempo Advertising March 2011

MemoPlus: Repeating pages

Walmark Tempo Advertising January 2011

Lego: Mind

LEGO Tempo Advertising October 2010

REPEATING PAGES

Walmark Tempo Advertising October 2010

Ultra Rapid Action Daily Gel Wash, Clearasil Ultra

Ultra Rapid Action Daily Gel Wash

Ultra Rapid Action Daily Gel Wash

Clearasil Ultra® Rapid Action Daily Gel Wash is dermatologist tested and gives you visibly clearer skin in as little as 12 hours. It is scientifically formulated with maximum strength acne medication and starts working quickly and help you get healthy looking skin. So you get visibly clearer skin fast.

Benefits

Clearer skin in as little as 12 hours

Rapid delivery of pimple fighting active

Dermatologist Tested

Available in 6.78 FL OZ tube

THE CLEARASIL ULTRA® GUARANTEE

Visibly Clearer Skin. WE GUARANTEE IT.

If you are not completely satisfied within 30 days of purchase, you may return it for a full refund. Simply send the unused portion of the Clearasil Ultra® product, along with the original, dated cash register receipt, and your full name and address to:

Reckitt Benckiser LLC. Attn: Consumer Relations P. O. Box 224 Parsippany, NJ 07054-0224

Please allow 6-8 weeks for delivery. Limit one refund per household. For more information, call 1-866-25-CLEAR.

(Salicylic acid wash-off cleanser)

Wet face

Dispense product into hands and massage gently onto face and neck, avoiding the delicate eye area

Cover the entire affected area with a thin layer and rinse thoroughly with warm water one to three times daily

Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor

If bothersome dryness or peeling occurs, reduce application to once a day or every other day

Main Active Ingredient

Maximum Strength Acne Medication (Salicylic Acid 2%)

The PHAs which give Ultra® treatments their edge as acne-fighting products are also antioxidant, helping protect the skin against damage caused by oxygen free radicals from UV or pollutant exposure.

The Ultra treatment products are based on 2% salicylic acid, but also contain polyhydroxy acids (PHAs), which are exclusive to Clearasil® and work alongside salicylic acid to open pores, improve skin moisturization and calm the skin. Clearasil® has enhanced the way that the active ingredients are delivered directly to the hair follicle (the root of the spot) and have called this Acceladerm™ Technology.

Acceladerm Technology™ improves product performance by unblocking pores and delivering salicylic acid deep into the pore fast. Salicylic acid is naturally lipophilic (oil-loving) so when applied to the skin it diffuses quickly into the oil-filled pores – exactly where spots form. These formulae are designed to be Clearasil’s® fastest ever.

A key ingredient in Clearasil® products is salicylic acid, which is a key skin-clearing ingredient.

unblocks pores by breaking up dead skin cells – the so called "keratolytic effect"

kills bacteria that cause inflamed spots

calms and soothes the skin (salicylic acid is closely related to aspirin)

kills bacteria that cause inflamed spots

calms and soothes the skin (salicylic acid is closely related to aspirin)

Ticinil, Ticinil

Standard Reference Data Program

Phenylbutazone

Formula : C 19 H 20 N 2 O 2

Molecular weight : 308.3743

IUPAC Standard InChI: InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3

IUPAC Standard InChIKey: VYMDGNCVAMGZFE-UHFFFAOYSA-N

CAS Registry Number: 50-33-9

Chemical structure: View the 3d structure.

Other names: 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-; Alindor; Antadol; Anuspiramin; Arthrizon; Artrizin; Artropan; Azolid; Benzone; Betazed; Bizolin 200; Bunetzone; Butacote; Butadion; Butadione; Butalidon; Butapirazol; Butartrina; Butazina; Butazolidin; Butazolidine; Butidiona; Butoz; Buzon; Diphebuzol; Diphenylbutazone; Ecobutazone; Fenibutal; Fenibutazona; Fenilbutina; Fenotone; Fenylbutazon; Flexazone; G 13,871; Ia-But; Kadol; Mephabutazon; Phebuzine; Pirarreumol B; Pyrabutol; R-3-ZON; Reudo; Reudox; Reumazin; Reumuzol; Robizone; Shigrodin; Tencodyne; Ticinil; Todalgil; Uzone; VAC-10; Zolaphen; Esteve; A 7514; Alkabutazona; Alqoverin; Anerval; Anpuzone; Artrizone; Azdid; Azobutyl; B. t.z.; Busone; Butaphen; Butacompren; Butadiona; Butagesic; Butalan; Butalgina; Butaluy; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butazona; Butazone; Bute; Butiwas-Simple; Butone; Butylpyrin; Buvetzone; Chembutazone; Digibutina; Diossidone; Diozol; Elmedal; Equi bute; Eributazone; Febuzina; Fenartil; Fenibutasan; Fenibutol; Fenilbutazona; Fenilbutine; Fenilidina; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Lingel; Malgesic; Mephabutazone; Merizone; Nadazone; Nadozone; Neo-zoline; Novophenyl; NCI-C55414; Phebuzin; Phen-Buta; Phenbutazol; Phenopyrine; Phenyl-Mobuzon; Phenylbutaz; Phenylbutazonum; Phenyzone; Praecirheumin; Pyrazolidin; PBZ; Rectofasa; Reumasyl; Reumazol; Reumune; Reupolar; Robizon-V; Rubatone; Scanbutazone; Schemergin; Tazone; Tetnor; Tevcodyne; Therazone; USAF GE-15; Wescozone; Zolidinum; Zorane; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; DA-192; 1,2-Diphenyl-3,5-dioxo-4-n-butylpyrazolidine; Equipalazone; Alkazone; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione

Permanent link for this species. Use this link for bookmarking this species for future reference.

Information on this page:

Mass spectrum (electron ionization)

References

Notes / Error Report

Other data available:

Phase change data

Gas Chromatography

Options:

Switch to calorie-based units

Data at NIST subscription sites:

Data compilation copyright by the U. S. Secretary of Commerce on behalf of the U. S.A. All rights reserved.

Spectrum

Notice: This spectrum may be better viewed with a Javascript and HTML 5 enabled browser.

Help

The interactive spectrum display requires a browser with JavaScript and HTML 5 canvas support.

Select a region with data to zoom. Select a region with no data or click the mouse on the plot to revert to the orginal display.

Credits

The following components were used in generating the plot:

Additonal code used was developed at NIST: jcamp-dx. js and jcamp-plot. js.

Use or mention of technologies or programs in this web site is not intended to imply recommendation or endorsement by the National Institute of Standards and Technology, nor is it intended to imply that these items are necessarily the best available for the purpose.

Additional Data

View image of digitized spectrum (can be printed in landscape orientation).

Download spectrum in JCAMP-DX format.

NIST Mass Spectrometry Data Center Collection (C) 2014 copyright by the U. S. Secretary of Commerce on behalf of the United States of America. All rights reserved.

Tox21 Consortium/NIST Mass Spectrometry Data Center, 2012

Search Chemicals

MyChemicals

PHENYLBUTAZONE

This compound is relatively stable at ambient temperatures. Aqueous decomposition of this chemical occurs by hydrolysis and oxidation. Insoluble in water.

Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)

SYMPTOMS: Symptoms of exposure to this compound include agranulocytosis, nausea, vomiting, epigastric pain, tinnitus, convulsions, coma, sodium retention, edema, aplastic anemia and leukopenia. Other symptoms include leukemia, cyanosis, respiratory depression, agitation, hallucinations, hypertension, reactivation of pre-existing peptic ulcers, ulcerative esophagitis, hepatic necrosis, glomerulonephritis, kidney stones, kidney failure, pericarditis, diffuse interstitial myocarditis with muscle necrosis, blood dyscrasias, hemolytic anemia, pancytopenia, optic neuritis causing blurred vision, toxic amblyopia, detached retina and allergic reactions such as rash, urticaria, arthralgia, Lyell's syndrome, Steven-Johnson syndrome, erythema multiforme and anaphylactic shock. It may cause kidney damage, bone marrow depression, excessive perspiring, stupor, ulceration of the buccal and gastrointestinal mucosa, cardiac toxicity, perivascular granulomata, thrombocytopenic purpura and exfoliative dermatitis. It may also cause fever, hematuria (blood in the urine), peptic ulcer, hypersensitivity reactions, hepatitis, sore throat, lesions in the mouth, dyspepsia, unusual bleeding or bruising, black or tarry stools or other evidence of intestinal ulceration, weight gain, thrombocytopenia, hemorrhagic diathesis, perforation, gastrointestinal bleeding, jaundice, death, abdominal discomfort and distress, indigestion, heartburn, water retention, abdominal distention with flatulence, constipation, diarrhea, gastritis, salivary gland enlargement, stomatitis (sometimes with ulceration), vasculitis, serum sickness, systemic lupus erythematosus, aggravation of temporal arteritis, pruritis, erythema nodosum, nonthrombocytopenic purpura, chloride retention, fluid retention, plasma dilution, congestive heart failure, metabolic acidosis, respiratory alkalosis, proteinuria, ureteral obstruction with uric acid crystals, anuria, nephrotic syndrome, impaired renal function, interstitial nephritis, headache, drowsiness, confusional states, lethargy, tremors, numbness, weakness, hyperglycemia hearing loss, scotomata, retinal hemorrhage, oculomotor palsy, thyroid hyperplasia, goiters associated with hyperthyroidism and hypothyroidism, pancreatitis, hematemesis, restlessness, dizziness, psychosis, hyperpyrexia, electrolyte disturbances, hyperventilation, hypotension, oliguria, cardiac arrest, anemia, leukocytosis and hypoprothrombinemia. Exposure may lead to vertigo, gastric irritation with ulceration, goiter, epidermal necrolysis, impaired hepati function and renal failure. Exposure may also lead to liver damage, degenerative changes in the brain, mental disturbances, difficulty in hearing, thready pulse, anorexia, pharyngeal membrane, enlargement of the liver and spleen, adrenol necrosis and uremia. Eye effects include a variety of eye disturbances, severe keratitis with involvement of the conjunctiva, cornea and tear glands which may result in scarring of the corneas with opacification vascularization and symblepharon, and rarely, diplopia. Granulocytopenia has occurred. Other symptoms may include insomnia, euphoria, nervousness and electrolyte retention.

ACUTE/CHRONIC HAZARDS: This compound is harmful if swallowed, inhaled or absorbed through the skin. It may cause irritation. When heated to decomposition it emits toxic fumes of carbon monoxide, carbon dioxide and nitrogen oxides. (NTP, 1992)

PHENYLBUTAZONE is incompatible with strong oxidizers, strong acids and strong bases. (NTP, 1992).

Belongs to the Following Reactive Group(s)

Potentially Incompatible Absorbents

No information available.

Response Recommendations

The Response Recommendation fields include isolation and evacuation distances, as well as recommendations for firefighting, non-fire response, protective clothing, and first aid. The information in CAMEO Chemicals comes from a variety of data sources.

Isolation and Evacuation

Excerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]:

As an immediate precautionary measure, isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids.

SPILL: Increase, in the downwind direction, as necessary, the isolation distance shown above.

FIRE: If tank, rail car or tank truck is involved in a fire, ISOLATE for 800 meters (1/2 mile) in all directions; also, consider initial evacuation for 800 meters (1/2 mile) in all directions. (ERG, 2016)

Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

STORAGE PRECAUTIONS: You should store this chemical under ambient temperatures, and protect it from moisture. (NTP, 1992)

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i. e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)

DuPont Tychem® Suit Fabrics

No information available.

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.

INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.

INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital.

OTHER: Since this chemical is a known or suspected carcinogen you should contact a physician for advice regarding the possible long term health effects and potential recommendation for medical monitoring. Recommendations from the physician will depend upon the specific compound, its chemical, physical and toxicity properties, the exposure level, length of exposure, and the route of exposure. (NTP, 1992)

Physical Properties

The Physical Property fields include properties such as vapor pressure and boiling point, as well as explosive limits and toxic exposure thresholds. The information in CAMEO Chemicals comes from a variety of data sources.

PharmGKB contains no dosing guidelines for this. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

= Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

The following icons indicate that data of a certain type is available:

DG Dosing Guideline information is available DL Drug Label information is available CA High-level Clinical Annotation is available VA Variant Annotation is available VIP VIP information is available PW Pathway is available

'Esteve'

Alindor

Alka Butazolidin

Alkabutazona

Alqoverin

Ambene

Anerval

Anpuzone

Antadol

Anuspiramin

Apo-Phenylbutazone

Arthrizon

Artizin

Artrizin

Artrizone

Artropan

Azdid

Azobutyl

Azolid

B. T.Z.

Benzone

Betazed

Bizolin

Bizolin 200

Bunetzone

Busone

Buta Phen

Butacompren

Butacote

Butadion

Butadiona

Butadione

Butagesic

Butalgina

Butalidon

Butaluy

Butapirazol

Butapirazole

Butapyrazole

Butarecbon

Butartril

Butartrina

Butatron

Butazina

Butazolidin

Butazolidine

Butazona

Butazone

Bute

Butidiona

Butiwas-Simple

Butone

Butoz

Butylpyrin

Buvetzone

Buzon

Chembutazone

Cotylbutazone

Digibutina

Diossidone

Diozol

Diphebuzol

Diphenylbutazone

Ecobutazone

Elmedal

Equi Bute

Equipalazone

Eributazone

Exrheudon N

Febuzina

Fenartil

Fenibutal

Fenibutasan

Fenibutazona

Fenibutol

Fenilbutazona

Fenilbutina

Fenilbutine

Fenilidina

Fenotone

Fenylbutazon

Ia-But

Intalbut

Intrabutazone

Intrazone

Ipsoflame

Kadol

Lingel

Malgesic

Mepha-Butazon

Mephabutazon

Mephabutazone

Merizone

Nadazone

Nadozone

Neo-Zoline

Novophenyl

Phebuzin

Phebuzine

Phenbutazol

Phenbutazone

Phenopyrine

Phenyl-Mobuzon

Phenylbutaz

Phenylbutazonum

Phenyzene

Phenyzone

Pirarreumol B

Praecirheumin

Pyrabutol

Pyrazolidin

Rectofasa

Reudo

Reudox

Reumasyl

Reumazin

Reumazol

Reumune

Reumuzol

Reupolar

Robizon-V

Robizone

Robizone-V

Rubatone

Scanbutazone

Schemergin

Shigrodin

Tazone

Tencodyne

Tetnor

Tevcodyne

Therazone

Ticinil

Todalgil

Usaf Ge-15

Uzone

VAC-10

Wescozone

Zolaphen

Zolidinum

Brand Mixture Names

Alka Phenyl Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)

Alka Phenylbutazone Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)

Phenylone Plus Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)

PharmGKB Accession Id

Type(s):

Description

A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

Source: Drug Bank

Indication

For the treatment of backache and ankylosing spondylitis

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Phenylbutazone binds to and inactivates prostaglandin H synthase and prostacyclin synthase through peroxide (H2O2) mediated deactivation. The reduced production of prostaglandin leads to reduced inflammation of the surrounding tissues.

Source: Drug Bank

Pharmacology

Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation

Source: Drug Bank

Food Interaction

Take with food to reduce irritation. Avoid alcohol.

The Encyclopedia Of Arda, Eladin

Elladan

In the one hundred and thirtieth year of the Third Age. Celebrían the wife of Elrond bore twin sons. Dark-haired and grey-eyed, only those that knew them well could tell them apart. The first of the twins was named Elladan . 'Elf - Man ' as a token of his ancestry; he was descended not only from the royal houses of the Eldar. but also from the Three Houses of the Edain .

Many centuries later, the twins' mother Celebrían went on a journey into the south to visit her own mother, Galadriel. in the land of Lórien. In the Redhorn Pass. she was captured by orcs. and tortured in their dens. Elladan rode with his brother to rescue her, but by the time they reached her she had received a poisonous wound. Though their father healed her, she would not remain in Middle-earth. and sailed into the West the following year. After this loss, Elladan and his brother Elrohir were filled with hatred of the orcs. often riding against them with the Northern Dúnedain .

In the early part of the War of the Ring. the brothers' main role was to scout the land and prepare the way for the Fellowship. but later they took a more active part. When Halbarad rode to Aragorn's aid with the Grey Company. Elladan and Elrohir accompanied them. They followed Aragorn through the Paths of the Dead. fought with him at Pelargir. and took part in the Battle of the Pelennor Fields. where they fought with stars bound to their brows.

After the War of the Ring. little is known of the brothers' fate. They returned to their father's house at Rivendell. and remained there even after he had passed across the Sea. Like their sister Arwen. the sons of Elrond Half-elven were granted the choice of whether to leave Middle-earth for the Undying Lands. or remain there and become Mortal as Men. Elladan had such a bond with his brother that they must surely have chosen alike, but what choice they made in the end can never now be known.

Notes

More precisely, as Tolkien notes in his Letters . ' Elladan might be translated "Elf - Númenórean "' ( The Letters of J. R.R. Tolkien . No 211, dated 1958). This is doubtless a reference to his dual descent from the noble houses of Elves and Edain .

Motrin - Pain Relief, Articalm

Motrin is used for treating rheumatoid arthritis, osteoarthritis, menstrual cramps, or mild to moderate pain. Motrin is an NSAID. NSAIDs treat the symptoms of pain and inflammation. They do not treat the disease that causes those symptoms.

Use Motrin as directed by your doctor.

Take Motrin by mouth with or without food. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.

Take Motrin with a full glass of water (8 oz/240 mL) as directed by your doctor.

If you miss a dose of Motrin and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about the proper use of Motrin .

Store Motrin at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Motrin out of the reach of children and away from pets.

Active Ingredient: Ibuprofen.

Do NOT use Motrin if:

you are allergic to any ingredient in Motrin

you have had a severe allergic reaction (eg, severe rash, hives, trouble breathing, growths in the nose, dizziness) to aspirin or an NSAID (eg, ibuprofen, celecoxib)

you have recently had or will be having bypass heart surgery

you are in the last 3 months of pregnancy.

Contact your doctor or health care provider right away if any of these apply to you.

Some medical conditions may interact with Motrin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal product, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of kidney or liver disease, diabetes, or stomach or bowel problems (eg, bleeding, perforation, ulcers)

if you have a history of swelling or fluid buildup, lupus, asthma, or growths in the nose (nasal polyps), or mouth inflammation

if you have high blood pressure, blood disorders, bleeding or clotting problems, heart problems (eg, heart failure), or blood vessel disease, or if you are at risk for any of these diseases

if you have poor health, dehydration or low fluid volume, or low blood sodium levels, you drink alcohol, or you have a history of alcohol abuse.

Some medicines may interact with Motrin. Tell your health care provider if you are taking any other medicines, especially any of the following:

Anticoagulants (eg, warfarin), aspirin, corticosteroids (eg, prednisone), heparin, or selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine) because the risk of stomach bleeding may be increased

Probenecid because it may increase the risk of Motrin 's side effects

Cyclosporine, lithium, methotrexate, or quinolones (eg, ciprofloxacin) because the risk of their side effects may be increased by Motrin

Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril) or diuretics (eg, furosemide, hydrochlorothiazide) because their effectiveness may be decreased by Motrin.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Motrin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Motrin may cause dizziness or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Motrin with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Serious stomach ulcers or bleeding can occur with the use of Motrin. Taking it in high doses or for a long time, smoking, or drinking alcohol increases the risk of these side effects. Taking Motrin with food will NOT reduce the risk of these effects. Contact your doctor or emergency room at once if you develop severe stomach or back pain; black, tarry stools; vomit that looks like blood or coffee grounds; or unusual weight gain or swelling.

Do not take more than the recommended dose or use for longer than prescribed without checking with your doctor.

Motrin has ibuprofen in it. Before you start any new medicine, check the label to see if it has ibuprofen in it too. If it does or if you are not sure, check with your doctor or pharmacist.

Do not take aspirin while you are using Motrin unless your doctor tells you to.

Lab tests, including kidney function, complete blood cell counts, and blood pressure, may be done to monitor your progress or to check for side effects. Be sure to keep all doctor and lab appointments.

Use Motrin with caution in the elderly; they may be more sensitive to its effects, including stomach bleeding and kidney problems.

Motrin should be used with extreme caution in children; safety and effectiveness in children have not been confirmed.

Pregnancy and breast-feeding: Motrin may cause harm to the fetus. Do not take it during the last 3 months of pregnancy. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Motrin while you are pregnant. It is not known if Motrin is found in breast milk. Do not breastfeed while taking Motrin .

All medicines can cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Constipation; diarrhea; dizziness; gas; headache; heartburn; nausea; stomach pain or upset.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; trouble breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or black, tarry stools; change in the amount of urine produced; chest pain; confusion; dark urine; depression; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; mental or mood changes; numbness of an arm or leg; one-sided weakness; red, swollen, blistered, or peeling skin; ringing in the ears; seizures; severe headache or dizziness; severe or persistent stomach pain or nausea; severe vomiting; shortness of breath; stiff neck; sudden or unexplained weight gain; swelling of hands, legs, or feet; unusual bruising or bleeding; unusual joint or muscle pain; unusual tiredness or weakness; vision or speech changes; vomit that looks like coffee grounds; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

Co-Amoxiclav 625mg Tablets, Medoclav

CO-AMOXICLAV 625MG TABLETS

Transcript

Patient Information Leaflet

Co-Amoxiclav 375mg and 625mg Tablets What you should know about this medicine. Please read this leaflet carefully before you start to take these tablets. If there is something you don’t understand, or if you have any other questions remember to ask your pharmacist or doctor. Keep this leaflet, you may want to read it again.

The name of this medicine is Co-amoxiclav Tablets. These tablets are available in two strengths. Co-amoxiclav Tablets 375mg are pale yellow, biconvex tablets embossed 375 on one side. The tablets contain two active ingredients, 250mg of amoxicillin (as trihydrate) and 125mg clavulanic acid (as potassium clavulanate). (These ingredients together are known as Co-amoxiclav).

Co-amoxiclav Tablets 625mg are pale yellow, oblong, biconvex tablets embossed 625 on one side. The tablets contain 500mg of amoxicillin (as trihydrate) and 125mg clavulanic acid (as potassium clavulanate). Both strengths of tablets also contain microcrystalline cellulose, quinoline yellow (E104), titanium dioxide (E171), crospovidone, Povidone K25, colloidal silicon dioxide, stearic acid, polyethylene glycol 6000, methylhydroxypropylcellulose, saccharin sodium, vanilla flavour and magnesium stearate. Co-amoxiclav Tablets 375mg and Co-amoxiclav Tablets 625mg are available as packs of 21 tablets.

How does this medicine work? Amoxicillin is an antibiotic. Antibiotics are used to treat infections caused by bacteria. When amoxicillin is combined with clavulanic acid it is effective against a wider range of bacteria than when used alone.

Product Licence Holder: Athlone Pharmaceuticals Limited, Ballymurray, Co. Roscommon, Ireland Manufactured by: Cimex AG, Birsweg 2, CH-4253 Liesburg, Switzerland.

Distributed by: Sovereign Medical, Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR.

Why am I taking Co-amoxiclav Tablets? They are used to treat respiratory tract infections such as bronchitis, pneumonia, sinusitis, tonsillitis and middle ear infections; infections of the kidneys, abdomen and lower urinary tract including cystitis; and skin and tissue infections.

Make sure that it is safe for you to take these tablets Sometimes it may not be suitable. You should check with your doctor if: you are sensitive or allergic to Co-amoxiclav Tablets or any of the ingredients, or to penicillin or other antibiotics you have ever developed serious liver problems when taking an antibiotic, you are pregnant, trying to become pregnant, or breast-feeding, you have liver or kidney problems, you have glandular fever, you are on a low potassium diet. Some drugs will inteefere with the action of Co-amoxiclav. Tell your doctor if you are taking any of these medicines other antibiotics such as chloramphenicol, erythromycin, sulfonamides, or tetracyclines, warfarin or other drugs to prevent blood clotting. The effect of drugs to thin the blood such as warfarin may be increased by Co-amoxiclav. If this happens there could be a risk of excessive bleeding. Allopurinol or probenecid for gout and related conditions.

Co-amoxiclav Tablets 375mg and 625mg contain 24.6mg potassium and so may be harmful to people who need to be on a low potassium diet. Co-amoxiclav Tablets do not interact with oral contraceptives and you should use other methods of contraception whilst taking these tablets.

You should always let your doctor know what other medicines you are taking, including any that have been prescribed by your doctor or you have bought.

Taking your medicine Take at regular intervals. Complete the prescribed course unless otherwise directed. You should always take these tablets as prescribed by your doctor. The instructions are usually on the pharmacist’s label. If you’re not sure about anything please ask your doctor or pharmacist. For infections: Dosage for adults (including the elderly) and children over 12: The usual dose is 375mg three times a day, preferably every 8 hours, for a maximum of 14 days. For more severe infections: One 625mg tablet three times a day. For dental infections: The usual dose is 375mg three times a day, preferably every 8 hours, for 5 days. The dose for people with severe liver or kidney problems may be less than these doses. The doctor will have decided what dose you need. These tablets are not suitable for children under 12 or weighing less than 40kg. Do not take more tablets than the doctor told you to take. Take the tablets for as long as the doctor told you to. Do not stop taking them because you feel better. If you are still unwell after finishing the course of tablets go and see your doctor. Swallow the tablets with a drink at the beginning of a meal. Do not break or chew the tablets. If you forget to take a tablet take one as soon as you remember, then carry on with the next dose. Try to wait about 4 hours before taking the next dose, and do not take two doses within about one hour or so. Never double-up on the dose to make up for the one you have missed. If you take too many tablets tell your doctor or the nearest hospital casualty department straight away. Let people know what you have taken. Are there any side-effects? Most people do not have any problems when they take these tablets, but nearly all medicines can cause side-effects in some people. Co-amoxiclav Tablets can sometimes cause stomach problems such as nausea (feeling sick), vomiting, indigestion or diarrhoea. These symptoms are usually mild and can be reduced by taking the tablets at the beginning of a meal. Very rarely, some people experience hyperactivity, dizziness, headache and convulsions. These symptoms are reversible. There have been rare reports of tooth discolouration. This can usually be removed by brushing. Some people may get thrush (a yeast infection of the vagina or mouth) when they take these tablets. You can get treatments for thrush from your pharmacist or doctor. If you notice anything else which you don’t understand ask your doctor or pharmacist’s advice. Some people can be allergic to antibiotics and can develop a rash. This can range in severity from a mid itchy rash to a rarer more serious condition which may cause ulceration of the mouth, lips and skin. Inflammation of the kidney can also occur rarely. In very rare cases, allergic reactions can include difficulty in breathing, fainting or swelling of the face and throat. Stop taking the tablets and tell your doctor if you develop any of these symptoms.

See your doctor immediately if you develop any of the following either while you are taking Coamoxiclav Tablets or in the weeks after finishing the treatment. Severe or prolonged diarrhoea with bleeding Darker urine or paler faeces Your skin or eyes becoming yellow Fever, bruising or bleeding. Co-amoxiclav Tablets can sometimes affect blood cell counts. Make sure that your doctor knows that you are taking these tablets if you are having blood tests. How to keep your tablets Keep all medicines in a safe place away from children. Do not store above 25oC. Store in the original package in order to protect from moisture. Keep the container tightly closed. Do not take the tablets after the date shown on the pack. REMEMBER this medicine was prescribed for you. You should not give it to anyone else even if you think their symptoms are similar. It may harm them.

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Budespray, Budespray

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Orlistat Uses, Dosage - Side Effects, Olistat

Orlistat

What is orlistat?

Orlistat blocks some of the fat that you eat, keeping it from being absorbed by your body.

Orlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. This medicine must be used together with a reduced-calorie diet. Orlistat is for use only in adults.

It is dangerous to purchase orlistat on the Internet or from vendors outside of the United States. Medications distributed from Internet sales may contain dangerous ingredients, or may not be distributed by a licensed pharmacy. Samples of "alli" purchased on the Internet have been found to contain sibutramine (Meridia), a prescription weight loss medication that can have dangerous side effects in certain people. For more information, contact the U. S. Food and Drug Administration (FDA) or visit www. fda. gov/buyonlineguide.

Important information

Do not take orlistat if you are pregnant. Weight loss is not recommended during pregnancy, even if you are overweight or obese.

You should not take orlistat if you have gallbladder problems or chronic malabsorption syndrome (an inability to absorb food and nutrients properly).

Before taking orlistat, tell your doctor if you have an underactive thyroid, a history of gallstones or pancreatitis, type 1 or type 2 diabetes, an eating disorder, liver disease, or if you take other weight-loss medications (prescription or over-the-counter).

Do not give the over-the-counter brand (alli) to a child younger than 18 years old. Prescription orlistat (Xenical) should not be used by anyone age 12 to 18 without the advice of a doctor. This medication should be used only by the person it was prescribed or recommended for and should never be shared with another person, especially someone who has a history of eating disorder. Keep the medication in a place where others cannot get to it.

Orlistat is only part of a complete program of treatment that also includes diet, exercise, and weight control. Your daily intake of fat, protein, and carbohydrates should be evenly divided over all of your daily meals. Follow your diet, medication, and exercise routines very closely.

Avoid a diet that is high in fat. High-fat meals taken in combination with orlistat can increase your risk of unpleasant side effects on your stomach or intestines.

Before taking this medicine

You should not take orlistat if you are allergic to it, or if you have:

chronic malabsorption syndrome (an inability to absorb food and nutrients properly); or

if you are pregnant.

Ask a doctor or pharmacist if it is safe for you to use orlistat if you have other medical conditions, especially:

type 1 or type 2 diabetes;

an eating disorder (anorexia or bulimia); or

if you take any other weight-loss medications (prescription or over-the-counter).

Do not use orlistat if you are pregnant. Weight loss is not recommended during pregnancy, even if you are overweight or obese. Stop taking this medicine and tell your doctor right away if you become pregnant.

Taking orlistat can make it harder for your body to absorb certain vitamins. These vitamins are important if you are nursing a baby. Do not use this medicine without a doctor's advice if you are breast-feeding a baby.

Prescription orlistat ( Xenical ) should not be given to a child younger than 12 years old. The over-the-counter brand ( alli ) is not approved for use by anyone younger than 18 years old.

How should I take orlistat?

Take orlistat exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Never share orlistat with another person, especially someone who has a history of eating disorder . Keep the medication in a place where others cannot get to it.

This medicine comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

Orlistat is usually taken 3 times per day with each main meal that contains some fat (no more than 30% of the calories for that meal). You may take the medicine either with your meal or up to 1 hour after eating.

If you skip a meal or you eat a meal that does not contain any fat, skip your orlistat dose for that meal.

The fat content of your daily diet should not be greater than 30% of your total daily caloric intake. For example, if you eat 1200 calories per day, no more than 360 of those calories should be in the form of fat.

Read the label of all food items you consume, paying special attention to the number of servings per container. Your doctor, nutrition counselor, or dietitian can help you develop a healthy eating plan.

Orlistat is only part of a complete program of treatment that also includes diet, exercise, and weight control. Your daily intake of fat, protein, and carbohydrates should be evenly divided over all of your daily meals. Follow your diet, medication, and exercise routines very closely.

Orlistat can make it harder for your body to absorb fat-soluble vitamins, such as vitamins A, D, E, and K. Your doctor may recommend that you take vitamin and mineral supplements while you are taking this medicine. Follow your doctor's instructions about the type of multi-vitamin or mineral supplement to use.

Take your vitamin or supplement at bedtime, or at least 2 hours before or after you take orlistat.

Store at room temperature away from moisture and heat. Keep the bottle tightly closed. Throw away any unused medicine after the expiration date on the medicine label has passed.

Keep track of the amount of medicine used from each new bottle. Orlistat is a drug that may be misused as a weight-loss aid, and you should be aware if anyone is using your medicine improperly or without a prescription.

What happens if I miss a dose?

Take the missed dose as soon as you remember, but no more than 1 hour after eating a meal. If it has been more than an hour since your last meal, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking orlistat?

Avoid a diet that is high in fat. High-fat meals taken in combination with orlistat can increase your risk of unpleasant side effects on your stomach or intestines.

If you also take cyclosporine, do not take it within 3 hours before or 3 hours after you take orlistat.

If you also take levothyroxine (such as Synthroid), do not take it within 4 hours before or 4 hours after you take orlistat.

Orlistat side effects

Get emergency medical help if you have any signs of an allergic reaction to orlistat: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using orlistat and call your doctor at once if you have:

severe pain in your lower back;

blood in your urine, painful or difficult urination;

kidney problems--little or no urinating; swelling in your feet or ankles; feeling tired or short of breath; or

liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Common orlistat side effects are caused by its fat-blocking action. These are signs that the medicine is working properly. These side effects are usually temporary and may lessen as you continue using orlistat:

oily or fatty stools;

oily spotting in your undergarments;

orange or brown colored oil in your stool;

gas and oily discharge;

loose stools, or an urgent need to go to the bathroom, inability to control bowel movements;

an increased number of bowel movements; or

stomach pain, nausea, rectal pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Orlistat dosing information

Usual Adult Dose for Obesity:

120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.

Usual Pediatric Dose for Obesity:

12 years or older: 120 mg orally three times a day with each main meal containing fat. The dose may be taken during the meal or within 1 hour of completing the meal.

What other drugs will affect orlistat?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with orlistat, especially:

insulin or oral diabetes medicine;

seizure medication (especially if your seizures get worse while taking orlistat;

a vitamin or mineral supplement that contains beta carotene or vitamin E; or

warfarin (Coumadin, Jantoven).

This list is not complete. Other drugs may interact with orlistat, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

More about orlistat

Consumer resources

Professional resources

Related treatment guides

Where can I get more information?

Your pharmacist can provide more information about orlistat.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2016 Cerner Multum, Inc. Version: 11.04. Revision Date: 2016-07-05, 2:50:13 PM.

Was this page helpful?

Clarithromycin - Fda Prescribing Information, Side Effects And Uses, Clorom

Clarithromycin

Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males. The plasma levels of Clarithromycin and 14-hydroxy-Clarithromycin were increased by the concomitant administration of omeprazole. For Clarithromycin, the mean C max was 10% greater, the mean C min was 27% greater, and the mean AUC 0-8 was 15% greater when Clarithromycin was administered with omeprazole than when Clarithromycin was administered alone. Similar results were seen for 14-hydroxy-Clarithromycin, the mean C max was 45% greater, the mean C min was 57% greater, and the mean AUC 0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.

Clarithromycin Tissue Concentrations 2 hours after Dose (mcg/mL)/(mcg/g)

Clarithromycin Clarithromycin + Omeprazole

10.48 ± 2.01 19.96 ± 4.71

20.81 ± 7.64 24.25 ± 6.37

4.15 ± 7.74 39.29 ± 32.79

For information about other drugs indicated in combination with Clarithromycin, refer to the CLINICAL PHARMACOLOGY section of their package inserts.

Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunit of susceptible bacteria resulting in inhibition of protein synthesis.

Clarithromycin is active in vitro against a variety of aerobic and anaerobic Gram-positive and Gram-negative bacteria as well as most Mycobacterium avium complex (MAC) bacteria.

Additionally, the 14-OH Clarithromycin metabolite also has clinically significant antimicrobial activity. The 14-OH Clarithromycin is twice as active against Haemophilus influenzae microorganisms as the parent compound. However, for Mycobacterium avium complex (MAC) isolates the 14-OH metabolite is 4 to 7 times less active than Clarithromycin. The clinical significance of this activity against Mycobacterium avium complex is unknown.

Clarithromycin has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:

Chlamydophila pneumoniae (TWAR) [previously Chlamydia pneumonia ]

Mycobacterium avium complex (MAC) consisting of:

Beta-lactamase production should have no effect on Clarithromycin activity.

NOTE: Most isolates of methicillin-resistant and oxacillin-resistant staphylococci are resistant to Clarithromycin.

Omeprazole/Clarithromycin dual therapy; ranitidine bismuth citrate/Clarithromycin dual therapy; omeprazole/Clarithromycin/amoxicillin triple therapy; and lansoprazole/Clarithromycin/amoxicillin triple therapy have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Clarithromycin pretreatment resistance rates were 3.5% (4/113) in the omeprazole/Clarithromycin dual therapy studies (M93-067, M93-100) and 9.3% (41/439) in the omeprazole/Clarithromycin/amoxicillin triple therapy studies (126, 127, M96-446). Clarithromycin pretreatment resistance was 12.6% (44/348) in the ranitidine bismuth citrate/Clarithromycin b. i.d. versus t. i.d. clinical study (H2BA3001). Clarithromycin pretreatment resistance rates were 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the lansoprazole/Clarithromycin/amoxicillin triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399).

Amoxicillin pretreatment susceptible isolates (<0.25 mcg/mL) were found in 99.3% (436/439) of the patients in the omeprazole/Clarithromycin/amoxicillin clinical studies (126, 127, M96- 446). Amoxicillin pretreatment minimum inhibitory concentrations (MICs) >0.25 mcg/mL occurred in 0.7% (3/439) of the patients, all of whom were in the Clarithromycin/amoxicillin study arm. Amoxicillin pretreatment susceptible isolates (<0.25 mcg/mL) occurred in 97.8% (936/957) and 98% (98/100) of the patients in the lansoprazole/Clarithromycin/amoxicillin triple therapy clinical trials by E-test and agar dilution, respectively. Twenty-one of the 957 patients (2.2%) by E-test and 2 of 100 patients (2%) by agar dilution had amoxicillin pretreatment MICs of >0.25 mcg/mL. Two patients had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of >256 mcg/mL by E-test

Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes *

Clarithromycin Pretreatment Results

Patients not eradicated of H. pylori following omeprazole/Clarithromycin, ranitidine bismuth citrate/Clarithromycin, omeprazole/Clarithromycin/amoxicillin, or lansoprazole/Clarithromycin/ amoxicillin therapy would likely have Clarithromycin resistant H. pylori isolates. Therefore, for patients who fail therapy, Clarithromycin susceptibility testing should be done, if possible. Patients with Clarithromycin resistant H. pylori should not be treated with any of the following: omeprazole/Clarithromycin dual therapy; ranitidine bismuth citrate/Clarithromycin dual therapy; omeprazole/Clarithromycin/amoxicillin triple therapy; lansoprazole/Clarithromycin/amoxicillin triple therapy; or other regimens which include Clarithromycin as the sole antimicrobial agent

Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes

In the omeprazole/Clarithromycin/amoxicillin triple therapy clinical trials, 84.9% (157/185) of the patients who had pretreatment amoxicillin susceptible MICs (<0.25 mcg/mL) were eradicated of H. pylori and 15.1% (28/185) failed therapy. Of the 28 patients who failed triple therapy, 11 had no post-treatment susceptibility test results, and 17 had post-treatment H. pylori isolates with amoxicillin susceptible MICs. Eleven of the patients who failed triple therapy also had post-treatment H. pylori isolates with Clarithromycin resistant MICs.

In the lansoprazole/Clarithromycin/amoxicillin triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (<0.25 mcg/mL) were eradicated of H. pylori. Of those with pretreatment amoxicillin MICs of >0.25 mcg/mL, three of six had the H. pylori eradicated. A total of 12.8% (22/172) of the patients failed the 10- and 14-day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy. Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had Clarithromycin resistant H. pylori isolates.

The following in vitro data are available, but their clinical significance is unknown. Clarithromycin exhibits in vitro activity against most isolates of the following bacteria; however, the safety and effectiveness of Clarithromycin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.

Streptococci (Groups C, F, G)

Viridans group streptococci

Gram-Negative Anaerobic Bacteria

Prevotella melaninogenica (formerly Bacteriodes melaninogenicus )

Susceptibility Testing Methods (Excluding Mycobacteria and Helicobacter)

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of Clarithromycin powder. The MIC values should be interpreted according to the following criteria 2 :

Susceptibility Test Interpretive Criteria for Staphylococcus aureus

Note: When testing Streptococcus pyogenes and Streptococcus pneumoniae. susceptibility and resistance to Clarithromycin can be predicted using erythromycin.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control bacteria to monitor and ensure the accuracy and precision of supplies and reagents in the assay, and the techniques of the individual performing the test 1,2. Standard Clarithromycin powder should provide the following MIC ranges.

* ATCC is a registered trademark of the American Type Culture Collection. † This quality control range is applicable only to S. pneumoniae ATCC 49619 tested by a microdilution procedure using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood. ‡ This quality control range is applicable only to H. influenzae ATCC 49247 tested by a microdilution procedure using HTM 1.

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method. 2,3 The procedure uses paper disks impregnated with 15 mcg of Clarithromycin to test the susceptibility of bacteria. The disk diffusion interpretive criteria are provided below.

Susceptibility Test Interpretive Criteria for Staphylococcus aureus.

Zone diameter (mm)

* These zone diameter standards only apply to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood incubated in 5% CO 2.

Susceptibility Test Interpretive Criteria for Streptococcus pyogenes and Streptococcus pneumoniae *

Zone diameter (mm)

* These zone diameter standards are applicable only to tests with Haemophilus spp. using HTM 2.

For testing Haemophilus spp. *

Zone diameter (mm)

Note: When testing Streptococcus pyogenes and Streptococcus pneumoniae. susceptibility and resistance to Clarithromycin can be predicted using erythromycin.

Standardized susceptibility test procedures require the use of laboratory control bacteria to monitor and ensure the accuracy and precision of supplies and reagents in the assay, and the techniques of the individual performing the test. 2,3 For the diffusion technique using the 15 mcg disk, the criteria in the following table should be achieved.

* This quality control range is applicable only to tests performed by disk diffusion using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood. † This quality control limit applies to tests conducted with Haemophilus influenzae ATCC 49247 using HTM 2.

Acceptable Quality Control Ranges for Clarithromycin

In vitro Activity of Clarithromycin Against Mycobacteria

Clarithromycin has demonstrated in vitro activity against Mycobacterium avium complex (MAC) microorganisms isolated from both AIDS and non-AIDS patients. While gene probe techniques may be used to distinguish M. avium species from M. intracellulare. many studies only reported results on M. avium complex (MAC) isolates.

Various in vitro methodologies employing broth or solid media at different pH’s, with and without oleic acid-albumin-dextrose-catalase (OADC), have been used to determine Clarithromycin MIC values for mycobacterial species. In general, MIC values decrease more than 16-fold as the pH of Middlebrook 7H12 broth media increases from 5 to 7.4. At pH 7.4, MIC values determined with Mueller-Hinton agar were 4- to 8-fold higher than those observed with Middlebrook 7H12 media. Utilization of oleic acid-albumin-dextrose-catalase (OADC) in these assays has been shown to further alter MIC values.

Clarithromycin activity against 80 MAC isolates from AIDS patients and 211 MAC isolates from non-AIDS patients was evaluated using a microdilution method with Middlebrook 7H9 broth. Results showed an MIC value of ≤4 mcg/mL in 81% and 89% of the AIDS and non-AIDS MAC isolates, respectively. Twelve percent of the non-AIDS isolates had an MIC value ≤0.5 mcg/mL. Clarithromycin was also shown to be active against phagocytized M. avium complex (MAC) in mouse and human macrophage cell cultures as well as in the beige mouse infection model.

Clarithromycin activity was evaluated against Mycobacterium tuberculosis microorganisms. In one study utilizing the agar dilution method with Middlebrook 7H10 media, 3 of 30 clinical isolates had an MIC of 2.5 mcg/mL. Clarithromycin inhibited all isolates at >10 mcg/mL.

Susceptibility Testing for Mycobacterium avium Complex (MAC)

The disk diffusion and dilution techniques for susceptibility testing against gram-positive and gram-negative bacteria should not be used for determining Clarithromycin MIC values against mycobacteria. In vitro susceptibility testing methods and diagnostic products currently available for determining minimum inhibitory concentration (MIC) values against Mycobacterium avium complex (MAC) organisms have not been standardized or validated. Clarithromycin MIC values will vary depending on the susceptibility testing method employed, composition and pH of the media, and the utilization of nutritional supplements. Breakpoints to determine whether clinical isolates of M. avium or M. intracellulare are susceptible or resistant to Clarithromycin have not been established

Susceptibility Test for Helicobacter pylori

The reference methodology for susceptibility testing of H. pylori is agar dilution MICs. 4 One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 10 7 - 1 x 10 8 CFU/mL for H. pylori ) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (>2-weeks old). The agar dilution plates are incubated at 35°C in a microaerobic environment produced by a gas generating system suitable for Campylobacter species. After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The Clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria:

* These are tentative breakpoints for the agar dilution methodology, and should not be used to interpret results obtained using alternative methods. † There were not enough organisms with MICs >0.25 mcg/mL to determine a resistance breakpoint.

These are quality control ranges for the agar dilution methodology and they should not be used to control test results obtained using alternative methods.

INDICATIONS AND USAGE

Clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below:

Adults (Clarithromycin Tablets)

Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of Clarithromycin in the subsequent prevention of rheumatic fever are not available at present.)

Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae.

Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis. or Streptococcus pneumoniae.

Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae. or Chlamydophila pneumoniae (TWAR).

Uncomplicated skin and skin structure infections due to Staphylococcus aureus. or Streptococcus pyogenes (Abscesses usually require surgical drainage).

Disseminated mycobacterial infections due to Mycobacterium avium. or Mycobacterium intracellulare.

Clarithromycin in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori .

Clarithromycin in combination with PRILOSEC (omeprazole) capsules or TIRTEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain Clarithromycin as the single antimicrobial agent are more likely to be associated with the development of Clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected Clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting.

In patients who fail therapy, susceptibility testing should be done if possible. If resistance to Clarithromycin is demonstrated, a non-Clarithromycin-containing therapy is recommended. (For information on development of resistance see MICROBIOLOGY section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence.

Children (Clarithromycin Tablets)

Pharyngitis/Tonsillitis due to Streptococcus pyogenes.

Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae. or Chlamydophila pneumoniae (TWAR).

Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae.

Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae.

Uncomplicated skin and skin structure infections due to Staphylococcus aureus. or Streptococcus pyogenes (Abscesses usually require surgical drainage).

Disseminated mycobacterial infections due to Mycobacterium avium. or Mycobacterium intracellulare.

Clarithromycin is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin and other antibacterial drugs, Clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

Clarithromycin is contraindicated in patients with a known hypersensitivity to Clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics.

Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/ hepatic dysfunction associated with prior use of Clarithromycin.

Concomitant administration of Clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see DRUG INTERACTIONS. ). There have been post-marketing reports of drug interactions when Clarithromycin and/or erythromycin are co-administered with cisapride, pimozide, astemizole or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by erythromycin and Clarithromycin. Fatalities have been reported.

Concomitant administration of Clarithromycin and colchicine are contraindicated in patients with renal or hepatic impairment.

Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes .

Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see WARNINGS ).

For information about contraindications of other drugs indicated in combination with Clarithromycin, refer to the CONTRAINDICATIONS section of their package inserts.

WARNINGS

Use In Pregnancy

Clarithromycin SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE. IF PREGNANCY OCCURS WHILE TAKING THIS DRUG, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. Clarithromycin HAS DEMONSTRATED ADVERSE EFFECTS OF PREGNANCY OUTCOME AND/OR EMBRYO-FETAL DEVELOPMENT IN MONKEYS, RATS, MICE, AND RABBITS AT DOSES THAT PRODUCED PLASMA LEVELS 2 TO 17 TIMES THE SERUM LEVELS ACHIEVED IN HUMANS TREATED AT THE MAXIMUM RECOMMENDED HUMAN DOSES (see PRECAUTIONS – Pregnancy ).

Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with Clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen. Discontinue Clarithromycin immediately if signs and symptoms of hepatitis occur.

Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during post-marketing surveillance in patients receiving Clarithromycin. Fatalities have been reported. Clarithromycin should be avoided in patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia (see CONTRAINDICATIONS ) and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.

Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia with disopramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e. g. verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older (see CONTRAINDICATIONS and PRECAUTIONS – Drug Interactions ). Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see PRECAUTIONS - Drug Interactions ).

Life-threatening and fatal drug interactions have been reported in patients treated with Clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of Clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, the dose of colchicine should be reduced. Patients should be monitored for clinical symptoms of colchicine toxicity. Concomitant administration of Clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment (see CONTRAINDICATIONS and PRECAUTIONS – Drug Interactions ).

Increased sedation and prolongation of sedation have been reported with concomitant administration of Clarithromycin and triazolobenzodiazepines, such as triazolam, and midazolam.

Use of quetiapine and Clarithromycin concomitantly with caution. Co-administration could result in increased quetiapine exposure and quetiapine related toxicities such as somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as Clarithromycin.

Oral Hypoglycemic Agents/Insulin

The concomitant use of Clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by Clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended.

There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when Clarithromycin is co-administered with warfarin. INR and prothrombin times should be frequently monitored while patients are receiving Clarithromycin and oral anticoagulants concurrently.

HMG-CoA Reductase Inhibitors (statins)

Concomitant use of Clarithromycin with lovastatin or simvastatin is contraindicated (see CONTRAINDICATIONS ) as these statins are extensively metabolized by CYP3A4, and concomitant treatment with Clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Cases of rhabdomyolysis have been reported in patients taking Clarithromycin concomitantly with these statins. If treatment with Clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.

Caution should be exercised when prescribing Clarithromycin with statins. In situations where the concomitant use of Clarithromycin with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should not exceed 40 mg daily. Use of a statin that is not dependent on CYP3A metabolism (e. g.fluvastatin) can be considered. It is recommended to prescribe the lowest registered dose if concomitant use cannot be avoided.

Clostridium difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile .

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile. and surgical evaluation should be instituted as clinically indicated.

Acute Hypersensitivity Reactions

In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), and Henoch-Schonlein purpura Clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.

Combination Therapy with Other Drugs

For information about warnings of other drugs indicated in combination with Clarithromycin, refer to the WARNINGS section of their package inserts.

PRECAUTIONS

General

Prescribing Clarithromycin tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate.

Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended in patients with creatinine clearance less than 25 mL/min (see DOSAGE AND ADMINISTRATION ).

Clarithromycin in combination with ranitidine bismuth citrate should not be used in patients with a history of acute porphyria.

Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving Clarithromycin therapy.

For information about precautions of other drugs indicated in combination with Clarithromycin tablets, refer to the PRECAUTIONS section of their package inserts.

Information to Patients

Patients should be counseled that antibacterial drugs including Clarithromycin tablets should only be used to treat bacterial infections. They do not treat viral infections (e. g. the common cold). When Clarithromycin tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Clarithromycin or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Clarithromycin tablets may interact with some drugs; therefore patients should be advised to report to their doctor the use of any other medications.

Clarithromycin tablets can be taken with or without food and can be taken with milk.

Drug Interactions

Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. In two studies in which theophylline was administered with Clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h Clarithromycin), the steady state levels of C max. C min. and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.

Hypotension, brady arrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.

Concomitant administration of single doses of Clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered.

When Clarithromycin and terfenadine were co-administered, plasma concentrations of the active acid metabolite of terfenadine were threefold higher, on average, than the values observed when terfenadine was administered alone. The pharmacokinetics of Clarithromycin and the 14-OH-Clarithromycin were not significantly affected by co-administration of terfenadine once Clarithromycin reached steady-state conditions. Concomitant administration of Clarithromycin with terfenadine is contraindicated (see CONTRAINDICATIONS ).

Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (C max. AUC 0-24. and t 1/2 increases of 30%, 89%, and 34%, respectively), by the concomitant administration of Clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with Clarithromycin.

Co-administration of Clarithromycin with ranitidine bismuth citrate resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-hydroxy-Clarithromycin plasma concentrations (31%). These effects are clinically insignificant.

Simultaneous oral administration of Clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Following administration of Clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. When Clarithromycin tablets were administered two to four hours prior to zidovudine, the steady-state zidovudine C max increased 100% whereas the AUC was unaffected (n=24). Administration of Clarithromycin and zidovudine should be separated by at least two hours. The impact of co-administration of Clarithromycin extended-release tablets and zidovudine has not been evaluated.

Simultaneous administration of Clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.

Following administration of fluconazole 200 mg daily and Clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state Clarithromycin C min and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH Clarithromycin were not significantly affected by concomitant administration of fluconazole. No dosage adjustment of Clarithromycin is necessary when co-administered with fluconazole.

Concomitant administration of Clarithromycin and ritonavir (n=22) resulted in a 77% increase in Clarithromycin AUC and a 100% decrease in the AUC of 14-OH Clarithromycin. Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. Since concentrations of 14-OH Clarithromycin are significantly reduced when Clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex (see PRECAUTIONS – Drug Interactions ). Doses of Clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.

Spontaneous reports in the post-marketing period suggest that concomitant administration of Clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving Clarithromycin and oral anticoagulants simultaneously.

Digoxin is a substrate for P-glycoprotein (Pgp) and Clarithromycin is known to inhibit Pgp. When Clarithromycin and digoxin are co-administered, inhibition of Pgp by Clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving Clarithromycin and digoxin concomitantly have been reported in post-marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.

Co-administration of Clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.

Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e. g. carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving Clarithromycin.

The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible.

Carbamazepine and Terfenadine

Increased serum concentrations of carbamazepine and the active acid metabolite of terfenadine were observed in clinical trials with Clarithromycin.

Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When a single dose of colchicine 0.6 mg was administered with Clarithromycin 250 mg BID for 7 days, the colchicine C max increased 197% and the AUC 0-∞ increased 239% compared to administration of colchicine alone. The dose of colchicine should be reduced when co-administered with Clarithromycin in patients with normal renal and hepatic function. Concomitant use of Clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment (see WARNINGS ).

Efavirenz, Nevirapine, Rifampicin, Rifabutin, and Rifapentine

Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of Clarithromycin, thus decreasing plasma concentrations of Clarithromycin, while increasing those of 14-OH-Clarithromycin. Since the microbiological activities of Clarithromycin and 14-OH-Clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of Clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. Concomitant administration of rifabutin and Clarithromycin resulted in an increase in rifabutin, and decrease in Clarithromycin serum levels together with an increased risk of uveitis.

Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-Clarithromycin, were increased. Because 14-OH-Clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to Clarithromycin should be considered for the treatment of MAC.

Sildenafil, Tadalafil, and Vardenafil

Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of Clarithromycin. Co-administration of Clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with Clarithromycin is not recommended.

The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with Clarithromycin.

Triazolobenzodiazepines (e. g. alprazolam, midazolam, triazolam)

When a single dose of midazolam was co-administered with Clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration. When oral midazolam is co-administered with Clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated. Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with Clarithromycin. For benzodiazepines which are not metabolized by CYP3A (e. g. temazepam, nitrazepam, lorazepam), a clinically important interaction with Clarithromycin is unlikely.

There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e. g. somnolence and confusion) with the concomitant use of Clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.

Both Clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Following administration of Clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the Clarithromycin AUC increased 94%, the 14-OH Clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%. When Clarithromycin is co-administered with atazanavir, the dose of Clarithromycin should be decreased by 50%. Since concentrations of 14-OH Clarithromycin are significantly reduced when Clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex (see PRECAUTIONS – Drug Interactions ). Doses of Clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.

Both Clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly. Clarithromycin may increase the plasma concentrations of itraconazole, while itraconazole may increase the plasma concentrations of Clarithromycin. Patients taking itraconazole and Clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.

Both Clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction. Following administration of Clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and C max increased 177% and 187% respectively compared to administration of saquinavir alone. Clarithromycin AUC and C max increased 45% and 39% respectively, whereas the 14-OH Clarithromycin AUC and C max decreased 24% and 34% respectively, compared to administration with Clarithromycin alone. No dose adjustment of Clarithromycin is necessary when Clarithromycin is co-administered with saquinavir in patients with normal renal function. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on Clarithromycin (refer to interaction between Clarithromycin and ritonavir) (see PRECAUTIONS — Drug Interactions ).

The following CYP3A based drug interactions have been observed with erythromycin products and/or with Clarithromycin in post-marketing experience:

There have been post-marketing reports of torsades de pointes occurring with concurrent use of Clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during co-administration of Clarithromycin with these drugs. Serum concentrations of these medications should also be monitored. There have been postmarketing reports of hypoglycemia with concomitant administration of Clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of Clarithromycin and disopyramide.

Postmarketing reports indicate that co-administration of Clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of Clarithromycin with ergotamine or dihydroergotamine is contraindicated (see CONTRAINDICATIONS ).

Triazolobenzodiazepines (Such as Triazolam and Alprazolam) and Related Benzodiazepines (Such as Midazolam)

Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. There have been post-marketing reports of drug interactions and CNS effects (e. g. somnolence and confusion) with the concomitant use of Clarithromycin and triazolam.

Quetiapine is a substrate for CYP3A4, which is inhibited by Clarithromycin. Co-administration with Clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as Clarithromycin.

Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. A similar interaction may occur with Clarithromycin; reduction of sildenafil dosage should be considered. (See Viagra package insert.)

There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or Clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital and St. John’s Wort.

Concomitant administration of Clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS ).

In addition, there have been reports of interactions of erythromycin or Clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.

Carcinogenesis, Mutagenesis, Impairment of Fertility

The following in vitro mutagenicity tests have been conducted with Clarithromycin:

Salmonella /Mammalian Microsomes Test

Bacterial Induced Mutation Frequency Test

In Vitro Chromosome Aberration Test

Rat Hepatocyte DNA Synthesis Assay

Mouse Lymphoma Assay

Mouse Dominant Lethal Study

Mouse Micronucleus Test

All tests had negative results except the In Vitro Chromosome Aberration Test which was weakly positive in one test and negative in another.

In addition, a Bacterial Reverse-Mutation Test (Ames Test) has been performed on Clarithromycin metabolites with negative results.

Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day (1.3 times the recommended maximum human dose based on mg/m 2 ) to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring. Plasma levels in rats after 150 mg/kg/day were 2 times the human serum levels.

In the 150 mg/kg/day monkey studies, plasma levels were 3 times the human serum levels. When given orally at 150 mg/kg/day (2.4 times the recommended maximum human dose based on mg/m 2 ), Clarithromycin was shown to produce embryonic loss in monkeys. This effect has been attributed to marked maternal toxicity of the drug at this high dose.

In rabbits, in utero fetal loss occurred at an intravenous dose of 33 mg/m 2. which is 17 times less than the maximum proposed human oral daily dose of 618 mg/m 2 .

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Clarithromycin.

Pregnancy

Pregnancy Category C :Four teratogenicity studies in rats (three with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of major organogenesis) and two in rabbits at oral doses up to 125 mg/kg/day (approximately 2 times the recommended maximum human dose based on mg/m 2 ) or intravenous doses of 30 mg/kg/day administered during gestation days 6 to 18 failed to demonstrate any teratogenicity from Clarithromycin. Two additional oral studies in a different rat strain at similar doses and similar conditions demonstrated a low incidence of cardiovascular anomalies at doses of 150 mg/kg/day administered during gestation days 6 to 15. Plasma levels after 150 mg/kg/day were 2 times the human serum levels. Four studies in mice revealed a variable incidence of cleft palate following oral doses of 1000 mg/kg/day (2 and 4 times the recommended maximum human dose based on mg/m 2. respectively) during gestation days 6 to 15. Cleft palate was also seen at 500 mg/kg/day. The 1000 mg/kg/day exposure resulted in plasma levels 17 times the human serum levels. In monkeys, an oral dose of 70 mg/kg/day (an approximate equidose of the recommended maximum human dose based on mg/m 2 ) produced fetal growth retardation at plasma levels that were 2 times the human serum levels.

There are no adequate and well-controlled studies in pregnant women. Clarithromycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see WARNINGS ).

Nursing Mothers

Clarithromycin and its active metabolite 14-hydroxy Clarithromycin are excreted in human milk. Serum and milk samples were obtained after 3 days of treatment, at steady state, from one published study of 12 lactating women who were taking Clarithromycin 250 mg orally twice daily. Based on the limited data from this study, and assuming milk consumption of 150 mL/kg/day, an exclusively human milk fed infant would receive an estimated average of 136 mcg/kg/day of Clarithromycin and its active metabolite, with this maternal dosage regimen. This is less than 2% of the maternal weight-adjusted dose (7.8 mg/kg/day, based on the average maternal weight of 64 kg), and less than 1% of the pediatric dose (15 mg/kg/day) for children greater than 6 months of age.

A prospective observational study of 55 breastfed infants of mothers taking a macrolide antibiotic (6 were exposed to Clarithromycin) were compared to 36 breastfed infants of mothers taking amoxicillin. Adverse reactions were comparable in both groups. Adverse reactions occurred in 12.7% of infants exposed to macrolides and included rash, diarrhea, loss of appetite, and somnolence.

Caution should be exercised when Clarithromycin is administered to nursing women. The development and health benefits of human milk feeding should be considered along with the mother’s clinical need for Clarithromycin and any potential adverse effects on the human milk fed child from the drug or from the underlying maternal condition.

Pediatric Use

Safety and effectiveness of Clarithromycin in pediatric patients under 6 months of age have not been established. The safety of Clarithromycin has not been studied in MAC patients under the age of 20 months. Neonatal and juvenile animals tolerated Clarithromycin in a manner similar to adult animals. Young animals were slightly more intolerant to acute overdosage and to subtle reductions in erythrocytes, platelets and leukocytes but were less sensitive to toxicity in the liver, kidney, thymus, and genitalia.

Geriatric Use

In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg every 12 hours, the maximum serum concentrations and area under the curves of Clarithromycin and 14-OH Clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function. In clinical trials, elderly patients did not have an increased incidence of adverse events when compared to younger patients. Dosage adjustment should be considered in elderly patients with severe renal impairment. Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients (see WARNINGS and PRECAUTIONS ).

Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e. g. verapamil, amlodipine, diltiazem, nifedipine) involved elderly patients 65 years of age or older (see WARNINGS ).

Adverse Reactions

The most frequent and common adverse reactions related to Clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and dysgeusia. These adverse reactions are consistent with the known safety profile of macrolide antibiotics.

There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.

Adverse Reactions Observed During Clinical Trials of Clarithromycin

The following adverse reactions were observed in clinical trials with Clarithromycin at a rate greater than or equal to 1%:

Gastrointestinal Disorders: Diarrhea, vomiting, dyspepsia, nausea, abdominal pain

Hepatobiliary Disorders: Liver function test abnormal

Immune System Disorders: Anaphylactoid reaction

Infection and Infestations: Candidiasis

Nervous System Disorders: Dysgeusia, headache

Psychiatric Disorders: Insomnia

Skin and Subcutaneous Tissue Disorders: Rash

Other Adverse Reactions Observed During Clinical Trials of Clarithromycin

The following adverse reactions were observed in clinical trials with Clarithromycin at a rate less than 1%:

Blood and Lymphatic System Disorders: Leukopenia, neutropenia, thrombocythemia, eosinophilia

Cardiac Disorders: Electrocardiogram QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations

Ear and Labyrinth Disorders: Vertigo, tinnitus, hearing impaired

Gastrointestinal Disorders: Stomatitis, glossitis, esophagitis, gastrooesophageal reflux disease, gastritis, proctalgia, abdominal distension, constipation, dry mouth, eructation, flatulence

General Disorders and Administration Site Conditions: Malaise, pyrexia, asthenia, chest pain, chills, fatigue

Hepatobiliary Disorders: Cholestasis, hepatitis

Immune System Disorders: Hypersensitivity

Infections and Infestations: Cellulitis, gastroenteritis, infection, vaginal infection

Investigations: Blood bilirubin increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, albumin globulin ratio abnormal

Metabolism and Nutrition Disorders: Anorexia, decreased appetite

Musculoskeletal and Connective Tissue Disorders: Myalgia, muscle spasms, nuchal rigidity

Nervous System Disorders: Dizziness, tremor, loss of consciousness, dyskinesia, somnolence

Psychiatric Disorders: Anxiety, nervousness

Renal and Urinary Disorders: Blood creatinine increased, blood urea increased

Respiratory, Thoracic and Mediastinal Disorders: Asthma, epistaxis, pulmonary embolism

Skin and Subcutaneous Tissue Disorders: Urticaria, dermatitis bullous, pruritus, hyperhidrosis, rash maculo-papular

In community-acquired pneumonia studies conducted in adults comparing Clarithromycin to erythromycin base or erythromycin stearate, there were fewer adverse events involving the digestive system in Clarithromycin-treated patients compared to erythromycin-treated patients (13% vs. 32%; p < 0.01). Twenty percent of erythromycin-treated patients discontinued therapy due to adverse events compared to 4% of Clarithromycin-treated patients.

In two U. S. studies of acute otitis media comparing Clarithromycin to amoxicillin/potassium clavulanate in pediatric patients, there were fewer adverse events involving the digestive system in Clarithromycin-treated patients compared to amoxicillin/potassium clavulanate-treated patients (21% vs. 40%, p < 0.001). One-third as many Clarithromycin-treated patients reported diarrhea as did amoxicillin/potassium clavulanate-treated patients.

The following adverse reactions have been identified during post approval use of Clarithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System Disorders: Thrombocytopenia, agranulocytosis

Cardiac Disorders: Torsades de pointes. ventricular tachycardia, ventricular arrhythmia

Ear and Labyrinth Disorders: Deafness was reported chiefly in elderly women and was usually reversible.

Gastrointestinal Disorders: Pancreatitis acute, tongue discoloration, tooth discoloration was reported and was usually reversible with professional cleaning upon discontinuation of the drug.

Hepatobiliary Disorders: Hepatic failure, jaundice hepatocellular. Adverse reactions related to hepatic dysfunction have been reported with Clarithromycin (see WARNINGS - Hepatotoxicity ).

Immune System Disorders: Anaphylactic reaction, angioedema

Infections and Infestations: Pseudomembranous colitis

Investigations: Prothrombin time prolonged, white blood cell count decreased, international normalized ratio increased. Abnormal urine color has been reported, associated with hepatic failure.

Metabolism and Nutrition Disorders: Hypoglycemia has been reported in patients taking oral hypoglycemic agents or insulin.

Musculoskeletal and Connective Tissue Disorders: Myopathy, rhabdomyolysis was reported and in some of the reports, Clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see CONTRAINDICATIONS and WARNINGS ).

Nervous System Disorders: Convulsion, ageusia, parosmia, anosmia, paraesthesia

Psychiatric Disorders: Psychotic disorder, confusional state, depersonalization, depression, disorientation, manic behavior, hallucination, abnormal behavior, abnormal dreams. These disorders usually resolve upon discontinuation of the drug.

There are no data on the effect of Clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.

Renal and Urinary Disorders: Nephritis interstitial, renal failure

Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne

Vascular Disorders: Hemorrhage

There have been reports of colchicine toxicity with concomitant use of Clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see WARNINGS and PRECAUTIONS ).

OVERDOSAGE

Overdosage of Clarithromycin can cause gastrointestinal symptoms such as abdominal pain, vomiting, nausea, and diarrhea.

Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, Clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.

DOSAGE AND ADMINISTRATION

Clarithromycin can be given with or without food.

Clarithromycin may be administered without dosage adjustment in the presence of hepatic impairment if there is normal renal function. In patients with severe renal impairment (CL CR < 30 mL/min), the dose of Clarithromycin should be reduced by 50%. However, when patients with moderate or severe renal impairment are taking Clarithromycin concomitantly with atazanavir or ritonavir, the dose of Clarithromycin should be reduced by 50% or 75% for patients with CL CR of 30 to 60 mL/min or < 30 mL/min, respectively.

ADULT DOSAGE GUIDELINES

H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Triple Therapy: Clarithromycin/lansoprazole/amoxicillin

The recommended adult dose is 500 mg Clarithromycin, 30 mg lansoprazole, and 1 gram amoxicillin, all given twice daily (q12h) for 10 or 14 days (see INDICATIONS AND USAGE and CLINICAL STUDIES sections).

Triple Therapy: Clarithromycin/omeprazole/amoxicillin

The recommended adult dose is 500 mg Clarithromycin, 20 mg omeprazole, and 1 gram amoxicillin, all given twice daily (q12h) for 10 days (see INDICATIONS AND USAGE and CLINICAL STUDIES sections). In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

Dual Therapy: Clarithromycin/omeprazole

The recommended adult dose is 500 mg Clarithromycin given three times daily (q8h) and 40 mg omeprazole given once daily (qAM) for 14 days (see INDICATIONS AND USAGE and CLINICAL STUDIES sections). An additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

Dual Therapy: Clarithromycin/ranitidine bismuth citrate

The recommended adult dose is 500 mg Clarithromycin given twice daily (q12h) or three times daily (q8h) and 400 mg ranitidine bismuth citrate given twice daily (q12h) for 14 days. An additional 14 days of 400 mg twice daily is recommended for ulcer healing and symptom relief. Clarithromycin and ranitidine bismuth citrate combination therapy is not recommended in patients with creatinine clearance less than 25 mL/min (see INDICATIONS AND USAGE and CLINICAL STUDIES sections).

The usual recommended daily dosage is 15 mg/kg/day divided q12h for 10 days.

PEDIATRIC DOSAGE GUIDELINES

The recommended dose of Clarithromycin for the prevention of disseminated Mycobacterium avium disease is 500 mg b. i.d. In children, the recommended dose is 7.5 mg/kg b. i.d. up to 500 mg b. i.d. No studies of Clarithromycin for MAC prophylaxis have been performed in pediatric populations and the doses recommended for prophylaxis are derived from MAC treatment studies in children. Dosing recommendations for children are in the table above.

Clarithromycin is recommended as the primary agent for the treatment of disseminated infection due to Mycobacterium avium complex. Clarithromycin should be used in combination with other antimycobacterial drugs that have shown in vitro activity against MAC or clinical benefit in MAC treatment (see CLINICAL STUDIES ). The recommended dose for mycobacterial infections in adults is 500 mg b. i.d. In children, the recommended dose is 7.5 mg/kg b. i.d. up to 500 mg b. i.d. Dosing recommendations for children are in the table above.

Clarithromycin therapy should continue if clinical response is observed. Clarithromycin can be discontinued when the patient is considered at low risk of disseminated infection.

HOW SUPPLIED

Clarithromycin Tablets USP

250 mg tablets are supplied as a round, white, film coated beveled edged, standard biconvex tablet, debossed with product identification “54 271” on one side and plain on the other side.

NDC 0054-0036-21: Bottle of 60 Tablets

500 mg tablets are supplied as a white, film coated, standard biconvex, capsule shaped tablet, debossed with product identification “54 312” on one side and plain on the other side.

NDC 0054-0037-21: Bottle of 60 Tablets

Store at 20° to 25

Valcote Generic Name Valproic Acid Online, Valcote

Valcote General Information

Valcote - Pharmacology:

Valcote binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Valcote may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.

Valcote for patients

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

This description is suitable for active ingredient Valproic Acid

Valcote Interactions

Effects of Co-Administered Drugs on Valproate Clearance : Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltrans-ferases, may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs.

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e. g. antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation.

Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn.

The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported.

Drugs for which a potentially important interaction has been observed: Aspirin - A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n=6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The ?-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8. 3% in the presence of aspirin. Caution should be observed if valproate and aspirin are to be co-administered.

Felbamate - A study involving the co-administration of 1200 mg/day of felbamate with valproate to patients with epilepsy (n=10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 µg/mL) compared to valproate alone. Increasing the felbamate dose to 2400 mg/day increased the mean valproate peak concentration to 133 µg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated.

Rifampin - A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin.

Drugs for which either no interaction or a likely clinically unimportant interaction has been observed: Antacids - A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate.

Chlorpromazine - A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate.

Haloperidol - A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels.

Cimetidine and Ranitidine - Cimetidine and ranitidine do not affect the clearance of valproate.

Effects of Valproate on Other Drugs : Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronosyltransferases.

The following list provides information about the potential for an influence of valproate co-administration on the pharma-cokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported.

Drugs for which a potentially important valproate interaction has been observed: Carbamazepine/carbamazepine-10, 11-Epoxide - Serum levels of carbamazepine (CBZ) decreased 17% while that of carba-mazepine-10, 11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients.

Clonazepam - The concomitant use of valproic acid and clonazepam may induce absence status in patients with a history of absence type seizures.

Diazepam - Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n=6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half-life of diazepam remained unchanged upon addition of valproate.

Ethosuximide - Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1600 mg/day) to healthy volunteers (n=6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs.

Lamotrigine - In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate.

Phenobarbital - Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n=6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate.

There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum con-centrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate.

Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate.

Phenytoin - Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n=7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%.

In patients with epilepsy, there have been reports of breakthrough seizures occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation.

Tolbutamide - From in vitro experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown.

Warfarin - In an in vitro study, valproate increased the unbound fraction of warfarin by up to 32. 6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if DEPAKOTE therapy is instituted in patients taking anticoagulants.

Zidovudine - In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected.

Drugs for which either no interaction or a likely clinically unimportant interaction has been observed: Acetaminophen - Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients.

Amitriptyline/Nortriptyline - Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline.

Clozapine - In psychotic patients (n=11), no interaction was observed when valproate was co-administered with clozapine.

Lithium - Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n=16) had no effect on the steady-state kinetics of lithium.

Lorazepam - Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n=9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.

Oral Contraceptive Steroids - Administration of a single-dose of ethinyloestradiol (50 µg)/levonorgestrel (250 µg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction.

Valcote Contraindications

Reclomide, Reclomide

Reclomide

Reclomide - General Information

A dopamine D2 antagonist that is used as an antiemetic. [PubChem]

Pharmacology of Reclomide

Reclomide, although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Reclomide is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Reclomide may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future.

Reclomide for patients

Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The ambulatory patient should be cautioned accordingly.

Reclomide Interactions

The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.

The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.

Absorption of drugs from the stomach may be diminished (e. g. digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e. g. acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).

Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.

Reclomide Contraindications

Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e. g. in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Metoclopramide is contraindicated in patients with pheochro-mocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phen-tolamine.

Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug.

Metoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

Additional information about Reclomide

Reclomide Indication: For the treatment of gastroesophageal reflux disease (GERD) Mechanism Of Action: Reclomide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Reclomide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Reclomide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals. Drug Interactions: Atovaquone The agent decreases the effect of atovaquone Cyclosporine Reclomide increases serum levels of cyclosporine Levodopa Levodopa decreases the effect of metoclopramide Succinylcholine The agent increases the effect of succinylcholine Venlafaxine Possible serotoninergic syndrome with this combination Food Interactions: Not Available Generic Name: Metoclopramide Synonyms: Metaclopramide; Metaclopromide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclopramida [Inn-Spanish]; Metoclopramide Hcl; Metoclopramide Hydrochloride; Metoclopramidum [Inn-Latin] Drug Category: Antiemetics; Prokinetic Agents; Dopamine Antagonists Drug Type: Small Molecule; Approved; Investigational Other Brand Names containing Metoclopramide: Apo-Metoclop; Cerucal; Clopra; Clopra-Yellow; Clopromate; DEL; Duraclamid; Elieten; Emetid; Emperal; Eucil; Gastrese; Gastro-Timelets; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metamide; Metoclol; Metoclopramide Intensol; Metoclopramide Omega; Metocobil; Metramid; Moriperan; Mygdalon; Neu-Sensamide; Nu-Metoclopramide; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pms-Metoclopramide; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Absorption: Rapidly and well absorbed (oral bioavailability 80±15.5%). Toxicity (Overdose): Oral, mouse LD 50 . 280 mg/kg. Signs of overdose include drowsiness, disorientation, and extrapyramidal reactions. Protein Binding: 30% Biotransformation: Hepatic Half Life: 5-6 hr Dosage Forms of Reclomide: Liquid Oral Liquid Intravenous Tablet Oral Liquid Intramuscular Chemical IUPAC Name: 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide Chemical Formula: C14H22ClN3O2 Metoclopramide on Wikipedia: http://en. wikipedia. org/wiki/Metoclopramide Organisms Affected: Humans and other mammals

Your #1 Choice For Boats For Sale In Maine, Zitrex

Your #1 Choice for Boats for Sale in Maine

Hamlin’s Marine wants you to enjoy every moment on the water.

For over twenty years Hamlin’s Marine has delivered on a simple promise… ”If you purchase a boat from Hamlin’s Marine, we’ll always be there when you need us.” Hamlin’s Marine offers convenience and assurance with our locations in Waterville and Hampden, staff of twenty-five dedicated employees, and a fleet of service trucks.

At Hamlin’s we only sell boats that we can stand behind. Our manufacturers include Bennington Pontoons. Stingray. Mastercraft. Cutwater. Northcoast. Puffin. Alumacraft. Achilles. Scout Boats. and Yamaha Outboards. These manufacturers lead the industry in quality construction, and make it easier to serve you when it matters most.

So come on in and choose from our selection of new and used Pontoon Boats, Tow Boats or any other fishing boats or family fun boats. With two easy locations in Waterville, Maine (Boat Sales and Service) or Hampden, Maine (Boat Sales, Service, and Marina) it couldn't get any more convenient. Choose Hamlin’s Marine as your boat dealer, service center, marina, and indoor storage facility, and we promise you’ll make wonderful memories on the water in Maine.

At Hamlin's Marine we stand behind all of our boats for sale in Maine .

Why Buy From Hamlin's Marine:

31 Years in Business

#1 Yamaha Outboard Dealer in New England for 5 Years in a Row

Alumacraft is America's #1 selling Deep V Aluminum Fishing Boat

Multiple Locations to serve you

Fleet of ten service and delivery trucks

Ax-Av Vitrax™ Pc Dvr, Vitrax

Access Control

AX-AV ViTrax™ PC DVR/Surveillance Client/Server Management Software

AX-AV ViTrax™ Multimedia Digital Video Surveillance & DVR PC Management Software is an advanced digital video recording and remote surveillance client/server software for Microsoft® Windows. The software supports live view, video recording and playback from major brand IP cameras of multiple local and remote sites in multi-client/multi-server installations, enabling the export of digital recordings for storage.

DVR Watchdog Recovery – Restarts the server automatically to resume local and remote data flow providing high level of reliability

Multi-Server, Multi-Client Support – Supports an unlimited number of cameras connected to the IP network on any geographical area and supports an unlimited number of ViTrax servers and can be viewed by an unlimited number of ViTrax clients

Proprietary Multi-media Database – Provides compact storage and efficient export of selected recordings for evidence preservation (own metadata)

Real-time multi-channel streaming video – ISO MPEG-4, Intel IPP, and DirectShow formats for effective compression and bandwidth savings

Support for console multi-screen viewing – Advanced OSD control and presence triggered by access control systems

License plate recognition – Allows reading license plate and automatically managing the vehicle access accordingly

Full support of all video parameters such as frame per second (fps), bit rate resolution, brightness and contrast; support up to 64 preset locations for PTZ cameras

Compatibility – Compatible with all major brand IP cameras, video servers, frame grabbers, and other devices including USB Webcams

Database Sharing – The shared database can be triggered by sending various events to an access control unit or Integrated security solution

Multilingual – Easily translated software for a wide range of language implementation

Mapping – Together with the Google Maps interface, you are able to place marked cameras on actual maps for easy browsing

related products

Emdesonid Rezeptfrei Kaufen ? Qualitat; ? Mit Niedrigen Preisen; ? Lieferung, Emdesonid

Pulmicort enthalt Budesonid, die ein Corticosteroid ist. Budesonid verhindert die Freisetzung von Stoffen im Korper, die die Entzundung verursachen.

Pulmicort wird verwendet, um Asthmaanfalle zu verhindern. Es wird nicht behandeln einen Asthmaanfall, die bereits begonnen hat. Es funktioniert durch eine Verringerung Reizung und Schwellung in den Atemwegen, die zu kontrollieren oder zu verhindern Asthma-Symptome hilft.

Pulmicort kann auch fur andere Zwecke als die aufgefuhrten verwendet werden.

Verwenden Sie Pulmicort genau wie es Ihnen verschrieben wurde. Verwenden Sie nicht die Medikamente in gro?eren Mengen, oder verwenden Sie es fur langer als empfohlen von Ihrem Arzt. Befolgen Sie die Anweisungen auf dem Etikett Verschreibung.

Verwenden Sie keine Pulmicort einen Asthmaanfall, die bereits begonnen hat, zu behandeln. Es wird nicht schnell genug arbeiten, um Ihre Symptome ruckgangig zu machen. Verwenden Sie nur ein schnell wirkendes Einatmen Medizin einen Asthma-Anfall zu behandeln.

Pulmicort wird mit Patienten-Anweisungen fur die sichere und wirksame Anwendung und Anweisungen zum Grundieren Sie den Inhalator Gerat. Befolgen Sie diese Anweisungen sorgfaltig. Fragen Sie Ihren Arzt oder Apotheker, wenn Sie irgendwelche Fragen haben.

Um die Wahrscheinlichkeit der Entwicklung einer Pilzinfektion im Mund zu reduzieren, spulen Sie den Mund mit Wasser nach der Verwendung von Pulmicort. Wenn Sie einen Zerstauber mit einer Gesichtsmaske, waschen Sie die Maske Bereich des Gesichts nach jedem Gebrauch.

Wenn Sie auch ein Steroid Medikamente, nicht aufhoren mit dem Steroid plotzlich oder Sie konnen unangenehme Entzugserscheinungen haben. Sprechen Sie mit Ihrem Arzt uber die Einnahme weniger der Steroid vor dem Anhalten vollstandig.

Fragen Sie Ihren Arzt, wenn Ihr Asthma-Symptome nicht nach der Verwendung von Pulmicort fur 2 Wochen bessern.

Asthma ist in der Regel mit einer Kombination von verschiedenen Medikamenten behandelt. Am besten behandeln Ihre Bedingung, verwenden Sie alle Ihre Medikamente, wie von Ihrem Arzt verordnet wurde. Andern Sie nicht Ihre Dosis oder Medikamenten Zeitplan ohne Beratung durch Ihren Arzt.

Ihre Dosierung Bedurfnisse konnen sich andern, wenn Sie eine Operation haben, krank sind, unter Stress stehen, oder kurzlich hatten einen Asthmaanfall. Sprechen Sie mit Ihrem Arzt, wenn Sie Ihre Asthma-Medikamente scheinen nicht so gut zu funktionieren Behandlung oder Vorbeugung von Asthmaanfallen.

Rufen Sie Ihren Arzt sofort, wenn Sie glauben, dass Pulmicort Ihr Zustand verschlimmert. Wenn es wie Sie mehr von einem Ihrer Medikamente in einer 24-Stunden-Zeitraum verwenden mussen scheint, mit Ihrem Arzt sprechen.

Um sicher zu sein Pulmicort ist nicht die schadliche Wirkungen verursacht, wird Ihr Arzt brauchen, um Ihre Fortschritte regelma?ig zu uberprufen. Verpassen Sie keine Termine geplant.

Mit einem Steroid kann die Blut-Zellen, die Ihren Korper der Bekampfung von Infektionen. Dies kann es fur Sie einfacher zu krank werden, mit anderen, die krank sind.

Bewahren Sie Pulmicort bei Raumtemperatur weg von Feuchtigkeit und Hitze. Bewahren Sie die Abdeckung auf dem Inhalationsgerat zwar nicht in Gebrauch ist.

Halten Sie den Streifen von Pulmicort Respules in der Folie Umschlag, vor Licht geschutzt, bis Sie bereit sind, die Medikamente zu verwenden sind. Nach Abrei?en einer Ampulle, kehren Sie den Streifen auf dem Umschlag, um die restlichen Ampullen vor Licht zu schutzen. Bewahren Sie die Folienumhullung aufrecht. Sobald Sie eroffnet einen Umschlag haben, mussen Sie die Ampullen innerhalb von 2 Wochen zu verwenden.

Die Pulmicort Flexhaler Gerat verfugt Indikatormarkierungen um Ihnen zu zeigen, wie viele Dosen sind innen links. Diese Dosis-counter Markierungen zeigen Schritten von 20 Dosen. Der Indikator kann nicht scheinen sich zu bewegen, bis etwa 5 Dosen verwendet wurden.

> Verwenden Sie keine zusatzliche Dosis ist, gerade weil die Flexhaler Indikator nicht sichtbar auf einen niedrigeren Wert nach einmaligem Gebrauch bewegt. Fragen Sie Ihren Apotheker, wenn Sie Fragen zu den Inhalator Gerat haben.

Ihre Pulmicort Rezept nachgefullt, bevor man den Bereich der Medizin vollig. Werfen Sie den alten Inhalationsgerat entfernt. Es ist eine Einweg-Behalter und kann nicht mit Budesonid nachgefullt werden.

Ersetzen Sie immer den Deckel. Shop Inhalator bei einer Raumtemperatur zwischen 59 und 86 Grad F (15 und 30 Grad C) an einem trockenen Ort fern von Feuchtigkeit.

Verwenden Sie keine Pulmicort einen Asthmaanfall, die bereits begonnen hat, zu behandeln. Es wird nicht schnell genug arbeiten, um Ihre Symptome ruckgangig zu machen. Verwenden Sie nur ein schnell wirkendes Einatmen Medizin einen Asthma-Anfall zu behandeln.

Fragen Sie Ihren Arzt, wenn Ihr Asthma-Symptome nicht nach der Verwendung von Pulmicort fur 2 Wochen bessern.

Rufen Sie Ihren Arzt sofort, wenn Sie denken, jede Ihrer Asthma-Medikamente sind nicht so gut funktioniert wie gewohnt. Ein erhohter Bedarf an Medikamenten konnte ein fruhes Zeichen einer schweren Asthmaanfall sein.

Ihre Dosierung von Pulmicort kann sich andern, wenn Sie eine Operation haben, krank sind, unter Stress stehen, oder kurzlich hatten einen Asthmaanfall. Sprechen Sie mit Ihrem Arzt, wenn Sie Ihre Asthma-Medikamente scheinen nicht so gut zu funktionieren Behandlung oder Vorbeugung von Asthmaanfallen.

Wenn Sie auch eine orale Steroid Medikamente, nicht aufhoren mit dem Steroid plotzlich oder Sie konnen unangenehme Entzugserscheinungen haben. Sprechen Sie mit Ihrem Arzt uber die Einnahme weniger der Steroid vor dem Anhalten vollstandig.

Sie sollten nicht Pulmicort wenn Sie allergisch auf Budesonid sind, oder wenn Sie einen akuten Asthmaanfall.

Bevor Sie Pulmicort, informieren Sie Ihren Arzt, wenn Sie allergisch auf alle Drogen, oder wenn Sie: Lebererkrankungen;

Herpes-simplex-Infektion der Augen;

jede Art von Bakterien-, Pilz oder viralen Infektion, oder

eine Geschichte der Tuberkulose.

FDA Schwangerschaft Kategorie B. Pulmicort ist nicht zu erwarten, als schadlich fur ein ungeborenes Kind. Informieren Sie Ihren Arzt, wenn Sie schwanger sind oder planen, wahrend der Behandlung schwanger werden. Budesonid kann in die Muttermilch uber und kann ein Saugling schaden. Verwenden Sie keine Pulmicort ohne Rucksprache mit Ihrem Arzt, wenn Sie stillen ein Baby.

Vermeiden Sie es, in der Nahe Menschen, die krank sind oder Infektionen. Rufen Sie Ihren Arzt fur eine vorbeugende Behandlung, wenn Sie Windpocken oder Masern ausgesetzt sind. Diese Bedingungen konnen schwere oder sogar todliche bei Menschen, die mit Steroiden werden.

Undergraduate Admissions, Corinael L

OUR TRADITION: "I would found an institution where any person can find instruction in any study." - Ezra Cornell, 1868

OUR TRADITION: "I would found an institution where any person can find instruction in any study." - Ezra Cornell, 1868

OUR TRADITION: "I would found an institution where any person can find instruction in any study." - Ezra Cornell, 1868

OUR TRADITION: "I would found an institution where any person can find instruction in any study." - Ezra Cornell, 1868

You are here

Undergraduate Admissions

Admissions Home QT

news

Schedule Your Visit

Browse information sessions, tours, activities, attractions and other campus events, and create your visit itinerary.

Cornell is home to seven undergraduate colleges and schools that offer nearly 80 majors and more than 4,000 courses. as well as challenging dual-degree programs.

With more than 1000 student organizations, an active public service center, and a vibrant fraternity and sorority community, there’s something for everyone at Cornell.

From Division 1 athletics, to intramural sports and on-campus fitness centers, Cornell has it all.

Cornell is one of the greatest research universities in the world, and providing undergraduates with research opportunities is a top priority.

Check out our lively residential communities and some of the best food and dining you’ll find at any U. S. college or university.

Cornell welcomes visitors all year long. Come and see our beautiful campus for yourself. Take a student-led walking tour. attend an admissions information session, join us for a Big Red hockey game, or attend a performance at Cornell’s Schwartz Center.

Schedule Your Visit

Browse information sessions, tours, activities, attractions and other campus events, and create your visit itinerary.

quick links

We are happy to provide you with general information about admissions, our students, academics, and financial aid at the university. In particular, the admissions data listed here are meant to give you a broad understanding of the kind of highly qualified candidates we admit to Cornell. These numbers should not be interpreted, however, to mean that objective data are the most important criteria in our selection process. Other factors, such as secondary school curriculum and performance, special talents, extracurricular activities, essays, and interviews (where required) are critical to our decision making as well.

Students in the Cornell Class of 2020 Come From. Australia • Azerbaijan • Bangladesh • Belgium • Brazil • Burundi • Canada • China • Ethiopia • Finland • Germany • Ghana • Hong Kong • India • Indonesia • Israel • Italy • Jamaica • Japan • Kenya • Korea • Madagascar • Malaysia • Maldives • Mauritius • Mexico • Mongolia • Morocco • Mozambique • Myanmar • Nepal • Netherlands • New Zealand • Nigeria • Norway • Pakistan • Peru • Poland • Portugal • Qatar • Russia • Rwanda • Saudi Arabia • Senegal • Singapore • South Africa • Spain • Sweden • Switzerland • Taiwan • Tanzania • Thailand • Tunisia • Turkey • Ukraine • United Kingdom • United States • Vietnam • Zambia • Zimbabwe

Class of 2020 Admissions:

University Totals for the 2015-2016 Admissions Cycle

Buy Mezarid - Atenolol - Online Without Prescriptions, Mezarid

Tenormin (Mezarid)

Tenormin is used to treat angina (chest pain) and hypertension (high blood pressure). Tenormin is used for decreasing death due to heart problems after a heart attack. Tenormin is a beta-blocker. Exactly how Tenormin works to decrease heart problems after a heart attack is not known.

Use Tenormin as directed by your doctor.

Do not take Tenormin in larger amounts or for longer than recommended by your doctor.

Take Tenormin with a full glass of water.

Take Tenormin at the same time every day.

Do not skip doses or stop taking Tenormin without first talking to your doctor. Stopping suddenly may make your condition worse.

To be sure this medication is helping your condition, your blood pressure will need to be checked on a regular basis. It is important that you not miss any scheduled visits to your doctor.

If you need to have any type of surgery, tell the surgeon that you are using Tenormin. You may need to briefly stop using Tenormin before having surgery.

Tenormin is only part of a complete program of treatment for hypertension that may also include diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely if you are being treated for hypertension.

Hypertension often has no symptoms, so you may not even feel that you have high blood pressure. Continue using this medicine as directed, even if you feel well. You may need to use blood pressure medication for the rest of your life.

Ask your health care provider any questions you may have about how to use Tenormin.

Store Tenormin at room temperature away from moisture and heat. Keep Tenormin out of the reach of children and away from pets.

Active Ingredient: Atenolol.

Do NOT use Tenormin if:

you are allergic to any ingredient in Tenormin

you have a very slow heartbeat, heart block, uncontrolled heart failure, shock caused by serious heart problems, or low blood pressure after a heart attack

you have an untreated adrenal gland tumor (pheochromocytoma)

you are taking mibefradil.

Contact your doctor or health care provider right away if any of these apply to you.

Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of any severe allergic reaction

if you have a history of lung or breathing problems (eg, asthma, chronic bronchitis, chronic obstructive pulmonary disease [COPD], emphysema), heart problems (eg, heart failure, conduction problems, left ventricle problems), blood vessel problems, diabetes, kidney problems, an adrenal gland tumor, or an overactive thyroid.

Some medicines may interact with Tenormin. Tell your health care provider if you are taking any of the following medicines.

Clonidine because the risk of severe high blood pressure may be increased

Mefloquine because the risk of irregular heartbeat may be increased

Amiodarone, calcium channel blockers (eg, diltiazem, verapamil), catecholamine-depleting medicines (eg, reserpine), digoxin, disopyramide, flecainide, ketanserin, mibefradil, or quinidine because they may increase the risk of Tenormin's side effects

Indomethacin or phenylpropanolamine because it may decrease Tenormin's effectiveness

Bupivacaine, lidocaine, or quinazolines (eg, alfuzosin) because the risk of their side effects may be increased by Tenormin.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tenormin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Tenormin may cause dizziness or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Tenormin with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Tenormin may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

Tell your doctor or dentist that you take Tenormin before you receive any medical or dental care, emergency care, or surgery.

Tenormin may reduce the amount of blood that flows to your feet and hands. This may cause them to feel cold and make you more sensitive to the cold. Dress warmly in cold weather. Be careful when you are out in the cold for long periods of time. Ask you doctor for more information.

If you have a history of any severe allergic reaction, talk with your doctor. You may be at risk for an even more severe allergic reaction if you come into contact with the substance that caused your allergy. Some medicines used to treat severe allergies may also not work as well while you are using Tenormin.

Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.

Diabetes patients - Tenormin may hide signs of low blood sugar such as a rapid heartbeat. Other symptoms, such as sweating, may still occur. Check your blood sugar levels regularly. Ask your doctor before you change the dose of your diabetes medicine.

Check your blood pressure and pulse regularly, as directed by your doctor. Ask your doctor or pharmacist for help if you are unsure how to properly measure your blood pressure or pulse.

Lifestyle changes may also help reduce your blood pressure. Talk with your doctor about appropriate diet and exercise programs that may be helpful to you.

Lab tests, including blood pressure and heart function tests, may be performed while you use Tenormin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

Use Tenormin with caution in the elderly; they may be more sensitive to its effects, especially dizziness.

Tenormin should be used with extreme caution in children; safety and effectiveness in children have not been determined.

Pregnancy and breast-feeding: Tenormin has been shown to cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Tenormin while you are pregnant. Tenormin is found in breast milk. If you are or will be breast-feeding while you use Tenormin, check with your doctor. Discuss any possible risks to your baby.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Cold fingers and toes; diarrhea; dizziness; drowsiness; nausea; tiredness or weakness.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blue fingernails, toenails, or palms; decreased sexual ability; fainting; mental or mood problems; persistent dizziness or lightheadedness; shortness of breath; sudden, unusual weight gain; swelling of hands, ankles, or feet; unusual bruising or bleeding; unusually slow heartbeat.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

Customers who bought this product also bought

Femara - Woman S Health, Letrozolum

Common use Femara is an oral, anti-estrogen drug which lowers estrogen levels in postmenopausal women to prevent certain types of breast cancer.

Dosage and direction The recommended dose of Femara in adults and elderly patients is 2.5 mg once a day. Take with a full glass of water with or without a meal. Follow all recommendations of your doctor. Your doctor may need you to be tested on a regular basis to control effectiveness of this medication. Do not miss any appointments. Your bone mineral density may also need a regular testing.

Precautions Inform your doctor if you have liver disease as you may need a dose adjustment or special safety tests. Do not start treatment with Femara if you are pregnant. When you are on this medication be sure about the use of effective birth control methods. Do not take more Femara than it was prescribed to you.

Femara is contraindicated in women who are pregnant. This medication may cause fetal harm when administered to a pregnant woman.

Side effects You may experience signs of allergic reaction such as hives, rash, difficulty breathing, facial swelling and also hot flashes, headache, night sweats, muscle or joint pain, fatigue, feeling weak, weight gain, nausea, swelling in the extremities. Stop taking the medication and contact your doctor if adverse reactions listed above get worse.

Drug interaction Concomitant use of Femara and tamoxifen by a daily dose of 20 mg leads to decrease of letrozole in blood concentrations. Caution should be exercised when letrozole is used together with drugs metabolized by cytochrome P450 isoenzymes (2A6 and 2S19). Inform your doctor about all medications, herbal products, food supplements and vitamins you use.

Missed dose If you missed a dose take it as soon as you remember. If it is almost time for your next dose just skip it and return to your regular schedule. Never take extra or double dose of Femara.

Overdose This medication is not likely to produce life-threating symptoms. Inform your doctor if you suspect that you took too much of this drug.

Storage Store at room temperature between 20-25 C (68-77 F). Store away from moisture, heat, and sunlight. It is not recommended to store in a bathroom and places available for children.

Disclaimer We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information on the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Penis Implants - Get The Facts On Penile Implant Surgery - Cost, Penles

5 Quick Cosmetic Treatments For Men Plastic surgery is increasingly becoming a guy thing. Here is the lowdown on the top five minimally invasive cosmetic procedures for today's man…

Penile Implants: A Surgical Option for Men with Erectile Dysfunction

Viagra and other drugs used to treat erectile dysfunction (ED) don't work for every man, but penis implants may help some men who do not respond to drugs. ED is a physical and psychological problem defined by the inability to maintain an erection long enough to engage in sexual intercourse.

Penis implants can help men achieve and maintain an erection. However, they do not improve sexual desire or sensation, nor do they increase penis length.

Penis Implant Surgery: Am I a Candidate?

Not all men are candidates for penis implant surgery. Those who are candidates include:

Men who have trouble achieving an erection and do not respond to ED drugs, suppositories, vacuum devices or injections.

Men with Peyronie's disease, a disorder marked by pain and bending of the penis during erection, if this disorder is accompanied by significant ED.

Your surgeon will take a careful history and perform a physical examination to determine if you are a candidate for penile implant surgery. During this exam, your surgeon will attempt to determine the cause of your ED as well as whether there are any co-existing problems such as loss of desire, inability to ejaculate or premature ejaculation. Your surgeon will also assess the length, stretchability and overall condition of your penis.

If you are deemed an appropriate candidate and decide to have penile implant surgery, you will receive an extensive list of preoperative instructions, including what medications you can and cannot take in the days leading up to your implant surgery. In addition, your surgeon might suggest that you bathe with antibiotic soap before your surgery to reduce the risk of infection. You will also be told not to shave the area yourself.

Types of Penile Implants

There are two main penile implants available: inflatable implants and semi-rigid rods.

Inflatable Implants. Inflatable penis implants are the most commonly used penile implant in the United States. Some inflatable implants are composed of two pieces, while others have three pieces.

In the two-piece model, two cylinders are inserted into the penis and attached to a pump in the scrotum. A small fluid-filled reservoir is part of this system.

Like the two-piece model, the three-piece model also has two cylinders that are inserted into the penis, and a larger fluid-filled reservoir. The models differ in that the three-piece model's reservoir is implanted under the abdominal wall, not in the scrotum.

Both inflatable models work in a similar fashion. Before intercourse, the man squeezes the pump, filling the cylinders with a saline solution from the reservoir; this causes an erection. After intercourse, he deflates the cylinders.

The three-piece penis implant usually produces a better erection than the two-piece system.

Benefits of inflatable penile implants include:

Ability to inflate and deflate on command

Reduced risk of damage to the inside of the penis that could come with constant internal pressure

Semi-rigid Rod Penis Implants. These penis implants are malleable rods placed within the erection chambers of the penis. They can be bent into an erect or non-erect position. These body implants are always firm, and as a result, there is constant pressure on the inside of the penis.

Benefits of semi-rigid rod penis implants include:

Less expensive than inflatable penis implants

Surgery is simpler than surgery with inflatable penis implants

Fewer parts than inflatable penile implants

Penis Implantation Procedure

Penis implantation surgery takes up to 90 minutes and can be performed on an outpatient basis. Some men may need to stay overnight at the hospital.

During the surgery — which involves the use of general or spinal anesthesia — a catheter is usually placed into the man's bladder through the urethra to drain urine. The catheter is typically removed within 24 hours after surgery.

The penile implant surgeon begins the operation by making an incision below the head of the penis, at the base of the penis or in the lower abdomen. The starting location is determined by the type of penile implant chosen, and the surgeon's preference.

Next, the surgeon dilates the corpora cavernosa, the tissue-filled chambers inside the penis. The surgical site is then flushed with antibiotic fluid to stave off infection, and the cylinders or semi-rigid rods are implanted inside the penis. If the implant surgery involves an inflatable penis implant, the surgeon places a pump inside the scrotum and a fluid-filled reservoir in the scrotum or lower abdomen. Once the device is in place, the surgeon closes the incisions.

There are several types of penile implants available.

Penile implants are used for men with erectile dysfunction that do not respond to other therapies, and men with certain diseases.

Penile implants will not make your penis longer.

Penile implants will not boost sexual desire or sensation.

Penile implants are usually covered by insurance.

Penile Implant Aftercare: What to Expect

Your surgeon will likely give you a list of instructions to follow after your penile implant surgery. This postoperative instruction list may include taking antibiotics to prevent infection and wearing loose-fitting underwear and clothing.

Most men can resume strenuous physical activity approximately one month after surgery and can resume sexual activity approximately four to six weeks after surgery.

Penile implant surgery is permanent. If the implant is removed, ED will return.

Penile Implantation: What are the Risks?

There are risks associated with all surgeries, including penile implant surgery. Notable risks of penile implantation include infection and mechanical failure. The more components an implant system has, the greater the risk of mechanical failure. For example, there is a greater risk of mechanical failure with a two - or three-piece inflatable implant than with a semi-rigid rod system. However, three-piece inflatable implants are considered the most effective, producing the best erections.

Penile Implants Surgery Cost

The cost of penis implant surgery includes the surgeon's fee, anesthesia fee, operating room fee and implant fee. Penis implantation surgery can cost up to $20,000, depending on the type of implant chosen. Medicare and many insurers will cover the cost of penile implant surgery, but may require precertification. Make sure to call your insurer and find out the exact policy before committing to surgery.

Choosing a skilled and experienced surgeon for your penile implant surgery is important. Board-certified urologists and plastic surgeons are the specialists with the most experience performing penile implant surgery. Start your search now.

Enlargement Options: All Hype, No Hope

Many men assume that penile implants increase size. They don't. While many companies hawk penis enlarging potions, pills and stretching weights, there is no evidence that these products will do anything more than deplete your wallet. In addition, these products may have risks attached to them, including impotence.

Unlike fat grafting to the breast and other parts of the body, fat injections to the penis are not considered an effective or safe method of enlarging the penis. Risks may include infection, bleeding and contour deformities. In addition, any gains in girth will likely be temporary, as the injected fat will likely be re-absorbed by your body in a few months. The bottom line is that there is no evidence backing the use of any methods of penile enlargement for cosmetic reasons. Buyer Beware!

Suggested Reading:

About the Reviewer of This Article

Drogo K. Montague, MD, is professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. In addition, he is director of the Center for Genitourinary Reconstruction in the Glickman Urological and Kidney Institute at the Cleveland Clinic, where he also serves as associate director of the urology residency program.

Dr. Montague completed his undergraduate education and attended medical school at the University of Michigan and received the degree Doctor of Medicine cum laude in 1968. He completed his residency training in urology at the Cleveland Clinic from 1968 to 1973 and has remained there since. He is certified by the American Board of Urology.

Dr. Montague has special interests in prosthetic surgery for both ED and urinary incontinence as well as penile reconstructive surgery for Peyronie's disease and congenital penile curvature.

Eposal, Eposal

Eposal

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Why register with MediGuard?

We are a free monitoring service designed for patients like you who want to be in the driver seat of your medical treatment. We have a community of more than 2.6 million members and offer the services below.

Medication Information Personalized Risk Rating Easy to understand overview Serious Side Effects Printable Medication List

Information you can understand Overview on Safety Alerts & Recalls Overview of Medications & Conditions

Community of patients Members’ Feedback Members Treatment Satisfaction

Health condition information Easy to understand overview Commonly Used Medications

Safety checks Safety Alerts & Recalls Drug - Drug Interaction Drug - Condition Interaction

Research participation Option to participate in medical surveys & studies*

Eposal (Carbamazepine)

Functional Java, Funcional

Overview

Functional Java is an open source library facilitating functional programming in Java. The library implements numerous basic and advanced programming abstractions that assist composition oriented development. Functional Java also serves as a platform for learning functional programming concepts by introducing these concepts using a familiar language.

The library is intended for use in production applications and is thoroughly tested using the technique of automated specification-based testing with ScalaCheck and Functional Java’s Quickcheck module. Functional Java is compiled with Java 8 targeting Java 6 bytecode. The use of lambdas within the project are backported with the Retro Lambda library, supporting Java versions 5 to 8 and beyond.

Features

Functional Java provides abstractions for the following types:

Basic Data Structures - total and partial functions, products, unit, option, unbiased and right biased unions (either and validation), void.

Immutable Collections - array, list, vector, stream, set, map, finger tree, priority queue, heterogenous list, difference lists.

Other Abstractions - monoid, semigroup, natural, random number generator, reader, writer, state, input/output, parser, zipper, specification based testing, actors, concurrency, optics (lens, prism, fold, traversal and others) and type conversion.

See the features page for a brief description of each of these types.

Example

Read the quick start guide for how to add FunctionalJava to your project and get started with a full example.

Functional Java includes numerous usage examples, this example maps a function over an array, adding 42 to each element (imports omitted).

Highfalutin - Definition Of Highfalutin By The Free Dictionary, Flutin

highfalutin

References in classic literature ?

All Moscow repeated Prince Dolgorukov's saying: "If you go on modeling and modeling you must get smeared with clay," suggesting consolation for our defeat by the memory of former victories; and the words of Rostopchin, that French soldiers have to be incited to battle by highfalutin words, and Germans by logical arguments to show them that it is more dangerous to run away than to advance, but that Russian soldiers only need to be restrained and held back

There was nothing highfalutin about her company manners--it was by this homely phrase that he differentiated this Dede on horseback from the Dede with the office manners whom he had always known.

I'm glad you didn't load him down with some highfalutin. romantic name that he'd be ashamed of when he gets to be a grandfather.

We don't believe that design is highfalutin ," Nixon said.

It's not a highfalutin view of cannabis," Berman said.

Highfalutin rubbish for telling us Kilkenny was going for a scan.

It's all-too-easy when you're sitting in a highfalutin private members clubs in London's snooty Soho quaffing drinks on expenses (again paid for by YOU) to forget that these are real lives being destroyed in the fanatical chase for ratings figures.

Democratization of the party, which, shorn of all its highfalutin effect, means not grovelling before The Family in the Congress, is one of those aspects close to the heart of the Amethi MP.

But lest this description make the whole thing sound too highfalutin or allusively "postmodern," rest assured that Lundgrens tricky Trude is his own creation, and that Norberg's dispirited search proves consistently moving and compelling.

Ditch all the highfalutin eco lingo and bigot bitching.

The management, with their ridiculous highfalutin titles - Director of Vision, puleeze - are bloated and don't do much apart from holding endless meetings and writing countless memos to each other.

He invited one of his highfalutin buddies, the president of Credit Default Swaps-R-Us, to come along.

Finural, Finural

Funerals and Memorial Services

Caring. com is a leading online destination for caregivers seeking information and support as they care for aging parents, spouses, and other loved ones. We offer thousands of original articles, helpful tools, advice from more than 50 leading experts, a community of caregivers, and a comprehensive directory of caregiving services.

The material on this site is for informational purposes only and is not a substitute for legal, financial, professional, or medical advice or diagnosis or treatment. By using our website, you agree to the Terms of Use and Privacy Policy . © Copyright 2007-2016 Caring, Inc. All Rights Reserved.

By using our website, you agree to the Terms of Use and Privacy Policy . © Copyright 2007-2016 Caring, Inc. All Rights Reserved.

Funeral. com

Why plan now for your funeral?

Planning your own funeral takes some pressure off of your loved ones during a difficult time. Plus, you can decide for yourself the type of service you’d like to have.

Instant Final Expense Coverage

No medical exam, phone interview or health questions

Quick and easy online enrollment with e-sign

Instant approval and coverage

A. M. Best rating A-Excellent

Premiums never increase, coverage is guaranteed for life

Policy accrues extra cash value over time

Choose your coverage $5,000 – $20,000

How much does a funeral cost?

Latest Blog Articles

Buy Medication Online Fast Delivery, High Quality, Lowest Prices, Discounts, Amiodarex

Viagra Active ingredient: Sildenafil $0.27 for pill Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension. Cialis Active ingredient: Tadalafil $0.68 for pill Cialis improves erection and helps to achieve a successful sexual intercourse.

Clomid Active ingredient: Clomiphene $0.44 for pill Clomid is a fertility drug, used to stimulate FSH and LH production and hereby the ovaries to produce eggs in ovarian disorders. ED Sample Pack 1 $2.31 for pill ED Sample Pack 1 consists of a two well-known medications (Viagra and Cialis) designed for the treatment of erectile dysfunction.

Brand Viagra Active ingredient: Sildenafil $2.56 for pill Brand Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension. Doxycycline $0.30 for pill Doxycyline is a tetracycline antibiotic used to treat infections of urinary tract, acne, gonorrhea, chlamydiosis, periodontitis, etc.

Propecia Active ingredient: Finasteride $0.51 for pill Propecia is used to treat hair loss (male pattern). Also it is used to treat prostate cancer and benign prostatic hyperplasia. Levitra Active ingredient: Vardenafil $1.00 for pill Levitra is used to treat sexual function problems such as Impotence or Erectile Dysfunction.

Amoxil Active ingredient: Amoxicillin $0.39 for pill Amoxil is an antibiotic from the penicillin group used to treat infections such as pneumonia, gonorrhea caused by E. coli, salmonella, etc. Viagra Professional Active ingredient: Sildenafil $0.57 for pill Viagra Professional is an extra-strength prescription medicine. It starts acting faster and the effect lasts longer that with regular Viagra.

Prednisone Active ingredient: prednisone $0.30 for pill Prednisone is used to reduce inflammation and alleviate symptoms in a variety of disorders, including rheumatoid arthritis and severe cases of asthma. Brand Cialis Active ingredient: Tadalafil $3.72 for pill Brand Cialis improves erection and helps to achieve a successful sexual intercourse.

Dapoxetine Active ingredient: Dapoxetine $0.95 for pill Dapoxetine is used as a treatment for premature ejaculation. Zithromax Active ingredient: Azithromycin $0.40 for pill Zithromax is a macrolide antibiotic to treat infections of upper and low respiratory tract, especially ear infections, pneumonia.

Nolvadex Active ingredient: tamoxifen $0.52 for pill Nolvadex (Tamoxifen) is used for treating breast cancer in women. Cytotec Active ingredient: Misoprostol $1.70 for pill Cytotec prevents formation of stomach ulcers in patients treated by NSAIDs or arthritis or pain medicines.

Cialis Professional Active ingredient: Tadalafil $1.20 for pill Cialis Professional is essentially a "new and improved" formula of the original Cialis®. While the product has been reformulated and enhanced in its. Viagra Super Active Active ingredient: Sildenafil $1.25 for pill Viagra Super Active is created to deliver maximum effect in the shortest time. It will take you only 10 minutes to feel the result.

Extra Super Viagra Active ingredient: dapoxetine $2.86 for pill Extra Super Viagra is used in the treatment of Erectile Dysfunction with Premature Ejaculation. Extra Super Viagra contains Sildenafil100 mg and Dapoxetine. Cialis Extra Dosage Active ingredient: Tadalafil $2.05 for pill Cialis Extra Dosage is indicated for the treatment of erectile dysfunction. Cialis Extra Dosage works faster than other ED drugs and lasts for an extended.

Cialis Soft Active ingredient: Tadalafil $1.11 for pill Cialis Soft improves erection and helps to achieve a successful sexual intercourse. Viagra Soft Active ingredient: Sildenafil $0.91 for pill Viagra Soft is a chewable tablet. Absorbed directly into the bloodstream, it acts faster. It is used to treat erection problems in men. The time necessary.

Kamagra Active ingredient: Sildenafil $0.90 for pill Kamagra is used for the treatment of erectile dysfunction in men and pulmonary arterial hypertension. Cipro Active ingredient: Ciprofloxacin $0.22 for pill Cipro is an antibiotic in a group of drugs called fluoroquinolones. It is used to treat different types of bacterial infections, e. g. bladder inflammation.

Cialis Super Active Active ingredient: Tadalafil $1.32 for pill Cialis Super Active increases testosterone levels, possesses enhanced vasodilating effect, increases sperm production and sexual arousal, stamina, and. Extra Super Cialis Active ingredient: tadalafil $3.06 for pill Extra Super Cialis is used in the treatment of Erectile Dysfunction with Premature Ejaculation. Extra Super Cialis 100mg contains Tadalafil 40 mg and.

Female Viagra Active ingredient: Sildenafil $0.68 for pill Female Viagra improves woman's sexuality, increases sensitivity to stimulation, allows to reach an intense sexual satisfaction. Lasix Active ingredient: Furosemide $0.25 for pill Lasix belongs to a class of diuretics, it is prescribed in patients with swelling caused by congestive heart failure.

Zoloft Active ingredient: Sertraline $0.28 for pill Zoloft is a selective serotonin reuptake inhibitor to treat depression, posttraumatic stress disorder, panic disorder, certain types of social anxiety. Propranolol Active ingredient: propranolol $0.27 for pill Propranolol works by decreasing the action of pacemaker cells and slowing certain impulses in the heart.

Xenical Active ingredient: Orlistat $0.79 for pill Xenical (Orlistat) is recommended and prescribed by pharmacists as a weight loss medication that targets the absorption of fat in your body rather than. Prednisolone $0.32 for pill Prednisolone is used for treating allergies, arthritis, breathing problems (e. g. asthma), certain blood disorders, collagen diseases (e. g. lupus), certain.

Tadapox Active ingredient: tadalafil $1.08 for pill Tadapox is a new combination tablet containing two of the most potent and effective pharmaceuticals proven to combat the major causes of male sexual. Metformin Active ingredient: metformin $0.26 for pill Metformin is a biguanide anti-diabetic that works by decreasing the amount of sugar that the liver produces and the intestines absorb.

Antabuse Active ingredient: Disulfiram $0.43 for pill Antabuse is used for treating alcoholism. Sildalis Active ingredient: tadalafil $0.95 for pill Sildalis is a combination drug, consisting both of Tadalafil and Sildenafil citrate (Viagra+Cialis). This combined medication is designed for the treatment.

Valtrex Active ingredient: Valacyclovir $2.66 for pill Valtrex is an antiviral drug used to treat herpes zoster, genital herpes, and herpes cold sores on the face and lips.

Viagra Active ingredient: Sildenafil $0.27 for pill Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension. Cialis Active ingredient: Tadalafil $0.68 for pill Cialis improves erection and helps to achieve a successful sexual intercourse.

Clomid Active ingredient: Clomiphene $0.44 for pill Clomid is a fertility drug, used to stimulate FSH and LH production and hereby the ovaries to produce eggs in ovarian disorders. ED Sample Pack 1 $2.31 for pill ED Sample Pack 1 consists of a two well-known medications (Viagra and Cialis) designed for the treatment of erectile dysfunction.

Brand Viagra Active ingredient: Sildenafil $2.56 for pill Brand Viagra is often the first treatment tried for erectile dysfunction in men and pulmonary arterial hypertension. Doxycycline $0.30 for pill Doxycyline is a tetracycline antibiotic used to treat infections of urinary tract, acne, gonorrhea, chlamydiosis, periodontitis, etc.

Propecia Active ingredient: Finasteride $0.51 for pill Propecia is used to treat hair loss (male pattern). Also it is used to treat prostate cancer and benign prostatic hyperplasia. Levitra Active ingredient: Vardenafil $1.00 for pill Levitra is used to treat sexual function problems such as Impotence or Erectile Dysfunction.

Amoxil Active ingredient: Amoxicillin $0.39 for pill Amoxil is an antibiotic from the penicillin group used to treat infections such as pneumonia, gonorrhea caused by E. coli, salmonella, etc. Viagra Professional Active ingredient: Sildenafil $0.57 for pill Viagra Professional is an extra-strength prescription medicine. It starts acting faster and the effect lasts longer that with regular Viagra.

Prednisone Active ingredient: prednisone $0.30 for pill Prednisone is used to reduce inflammation and alleviate symptoms in a variety of disorders, including rheumatoid arthritis and severe cases of asthma. Brand Cialis Active ingredient: Tadalafil $3.72 for pill Brand Cialis improves erection and helps to achieve a successful sexual intercourse.

Dapoxetine Active ingredient: Dapoxetine $0.95 for pill Dapoxetine is used as a treatment for premature ejaculation. Zithromax Active ingredient: Azithromycin $0.40 for pill Zithromax is a macrolide antibiotic to treat infections of upper and low respiratory tract, especially ear infections, pneumonia.

Nolvadex Active ingredient: tamoxifen $0.52 for pill Nolvadex (Tamoxifen) is used for treating breast cancer in women. Cytotec Active ingredient: Misoprostol $1.70 for pill Cytotec prevents formation of stomach ulcers in patients treated by NSAIDs or arthritis or pain medicines.

Cialis Professional Active ingredient: Tadalafil $1.20 for pill Cialis Professional is essentially a "new and improved" formula of the original Cialis®. While the product has been reformulated and enhanced in its. Viagra Super Active Active ingredient: Sildenafil $1.25 for pill Viagra Super Active is created to deliver maximum effect in the shortest time. It will take you only 10 minutes to feel the result.

Extra Super Viagra Active ingredient: dapoxetine $2.86 for pill Extra Super Viagra is used in the treatment of Erectile Dysfunction with Premature Ejaculation. Extra Super Viagra contains Sildenafil100 mg and Dapoxetine. Cialis Extra Dosage Active ingredient: Tadalafil $2.05 for pill Cialis Extra Dosage is indicated for the treatment of erectile dysfunction. Cialis Extra Dosage works faster than other ED drugs and lasts for an extended.

Cialis Soft Active ingredient: Tadalafil $1.11 for pill Cialis Soft improves erection and helps to achieve a successful sexual intercourse. Viagra Soft Active ingredient: Sildenafil $0.91 for pill Viagra Soft is a chewable tablet. Absorbed directly into the bloodstream, it acts faster. It is used to treat erection problems in men. The time necessary.

Kamagra Active ingredient: Sildenafil $0.90 for pill Kamagra is used for the treatment of erectile dysfunction in men and pulmonary arterial hypertension. Cipro Active ingredient: Ciprofloxacin $0.22 for pill Cipro is an antibiotic in a group of drugs called fluoroquinolones. It is used to treat different types of bacterial infections, e. g. bladder inflammation.

Cialis Super Active Active ingredient: Tadalafil $1.32 for pill Cialis Super Active increases testosterone levels, possesses enhanced vasodilating effect, increases sperm production and sexual arousal, stamina, and. Extra Super Cialis Active ingredient: tadalafil $3.06 for pill Extra Super Cialis is used in the treatment of Erectile Dysfunction with Premature Ejaculation. Extra Super Cialis 100mg contains Tadalafil 40 mg and.

Female Viagra Active ingredient: Sildenafil $0.68 for pill Female Viagra improves woman's sexuality, increases sensitivity to stimulation, allows to reach an intense sexual satisfaction. Lasix Active ingredient: Furosemide $0.25 for pill Lasix belongs to a class of diuretics, it is prescribed in patients with swelling caused by congestive heart failure.

Zoloft Active ingredient: Sertraline $0.28 for pill Zoloft is a selective serotonin reuptake inhibitor to treat depression, posttraumatic stress disorder, panic disorder, certain types of social anxiety. Propranolol Active ingredient: propranolol $0.27 for pill Propranolol works by decreasing the action of pacemaker cells and slowing certain impulses in the heart.

Xenical Active ingredient: Orlistat $0.79 for pill Xenical (Orlistat) is recommended and prescribed by pharmacists as a weight loss medication that targets the absorption of fat in your body rather than. Prednisolone $0.32 for pill Prednisolone is used for treating allergies, arthritis, breathing problems (e. g. asthma), certain blood disorders, collagen diseases (e. g. lupus), certain.

Tadapox Active ingredient: tadalafil $1.08 for pill Tadapox is a new combination tablet containing two of the most potent and effective pharmaceuticals proven to combat the major causes of male sexual. Metformin Active ingredient: metformin $0.26 for pill Metformin is a biguanide anti-diabetic that works by decreasing the amount of sugar that the liver produces and the intestines absorb.

Antabuse Active ingredient: Disulfiram $0.43 for pill Antabuse is used for treating alcoholism. Sildalis Active ingredient: tadalafil $0.95 for pill Sildalis is a combination drug, consisting both of Tadalafil and Sildenafil citrate (Viagra+Cialis). This combined medication is designed for the treatment.

Valtrex Active ingredient: Valacyclovir $2.66 for pill Valtrex is an antiviral drug used to treat herpes zoster, genital herpes, and herpes cold sores on the face and lips.

Mi Experiencia Con El Roacutan, Roacnetan

Mi experiencia con el Roacutan

Hola, en este post voy a explicarles todo lo que ocurrio durante el transcurso que tome esta magica pastilla. Yo tuve acne 4 anos atras, y me fui al dermatologo y me dio un par de gel que fueron totalmente ineficaces, luego me recomendo el Roacutan, pero mi mama (en ese tiempo tenia 13 anos) me lo prohibio totalmente que tome, asi que me hizo cambiar de dermatologo. El rechazo de mi mama se debio a la gran cantidad de efectos secundarios. Me hice tratar 2 anos con distintos productos entre gel, jabon, comida sana, etc..recomendados por un dermatologo y NADA dio resultado, va, capaz me mejoro 2% en 2 anos, osea NADA. Hasta que la dermatologa nueva me fue sincera y me dijo, ningun producto te va a dejar la cara como te deja el Roacutan, hace 25 anos trabajo con esta pastilla y nunca un paciente vino con efectos secundarios (que no sean los comunes como labio seco). Asi que accedi a tomar la pastilla, recuerdo que estaba muy nervioso, por tooooooooodos los efectos secundarios que tenia, entre las que se destacaban: Ideas suicida Intentos de suicidio Discapacidad auditiva (de por vida) Pseudotumor cerebral Pancreatitis Trombosis Vascular(ataque al corazon) Paro cardiorespiratorio Convulsiones

y un muchas mas efectos secundarios que no vienen al caso ponerlas. La dermatologa me pidio que me hiciera unos analisis para poder verificar que mi cuerpo iba a tolerar el medicamento, asi que me lo realice (te sacan un poco de sangre y listo) y me dio bien el higado, los globulos, azucar y todo eso. asi que comence. Realice un tratamiento por 8 meses que consistia en tomar 2 pastillas de 20mg (las 2 juntas) durante el desayuno. La doctora me recomendo tomarlo con productos lacteos, como leche y yogur ya que asi absorve mejor el efecto. Y ahora una recomendacion mia, tratar de tomar la leche sin azucar, porque digo esto? Porque la pastilla ya te sube el azucar, e imaginate si tomas todos los dia un vaso con azucar. Pero igualmente esto no modifica en nada, porque casi siempre tomamos gaseosa, y un vaso de gaseosa tiene mucho mas azucar xd. Bueno voy a explicar mas o menos como fue, yo tenia la cara con acne mmmmm. moderado podriamos decir, mas que nada tenia marcas de haberme reventado los granos anteriormente. El primer mes no senti efectos secundarios alguno, eso si, seguramente ustedes se preguntaran sobre el acne fulminante, osea lo que te dicen los medicos que al tomar la pastilla te va a salir todos los granos internos hacia afuera. Y SI me paso, pero muy leve, osea me salian 2 super granos, o 1 solo, por suerte me salian en puntos estrategicos jaj, como en la frente donde va el flequillo, o en el cuello donde te tapa la campera/camisa/chomba, etc. Si son mujeres, traten de no maquillarse, en todo caso averiguen con la dermatologa, para que les recomiende maquillajes que no tapen los poros. Asi que el primer mes fue un leve brote, luego del primer mes empece a sentir lo "mas insoportable" de la pastilla. los labios secos! De esto no se van a escapar jaj, si los labios no se secan es porque la pastilla no esta funcionando, osea la pastilla te seca todo, entre esos el labio. Voy a explicar mi experiencia con la manteca de cacao, al comienzo me compre las simples esas, las que no tienen ni marca y estan 2$, esas no me funcionaron para nada, tenia muy seco el labio para una manteca tan debil, asi que compre la manteca de nivea color naranja, esas no use porque tenia protector y me dejaba blanco el labio y ademas era debil, no me hacia efecto. Luego compre la manteca de cacao nivea azul, estas son un arma de doble filo xd, son BUENISIMAS, son muuuy hidratantes. peeeeero, si sos hombre te va a quedar brilloso jaj y segundo es tan pero tan graso la manteca de cacao que hace que tengas perfecto el labio pero te saca granos alrededor! porque es muy graso! Asi que cambie y me compre la que use hasta ultimo momento y es con la que me fue mejor. la manteca de cacao se llamaba Chapstick y era de color azul, es hidratante pero no tanto como la nivea, asi que no te saca granos (va me salian un par con esto, pero no tengo como la nivea, trata de ponerte solo en el labio y no en la piel). Luego del primer mes me realice un analisis y me dio que todo estaba OK, asi que segui adelante. Bueno asi era mi primer mes y medio, no veia mejoras en la cara y ya tenia los insoportables labios secos. En el segundo mes empece a ver una leve mejoria y seguia teniendo labios secos y un par de veces me habia sangrado la nariz (no te sangra sin motivo. te sangra cuando te tocas ) Al tercer mes ya tenia la cara un poco mejor, habia mejorado en un 40%. no me habia sangrado la nariz y los labios si tenia seco. En el cuarto mes ya tenia la cara super mejor. Aclaro algo que me olvide de decir mas arriba, desde inicios del segundo mes aproximadamente ya no te salen mas granos! ya se centra en lo que son las marcas, las cicatrices y hace que no te salgan mas. En este cuarto mes tenia un 80% la cara lisa! obviamente sin granos en estos meses, y con un poco de marcas. Labios secos todavia! (muy molesto esto). Otro analisis para confirmar que seguia bien! En el 5? mes, me sangro 3 dias la nariz (eso porque me tocaba jaja) y la cara perfecta. En el 6? mes, no me sangro, pero si labios secos, y mi cara era sonada xd. En el 7? mes, me sangro la nariz por tocarme jaj, labios secos. y mi piel ya era hermosa! En el 8? mes, lo mismo de siempre, nariz sangrando un par de dias, labios muuy secos, pero tenia una piel de bebe! 0 marcas, 0 granos, 0 manchas. no tenia nada, volvia a tener la cara que me gustaba, sin los granos molestos. Es mas, creo que hasta extranas reventarte un grano xd (no mentira no se extrana) Hace medio mes termine las pastillas, me hice un analisis, todo bien salio! No tengo labios secos y ya no me sangra la nariz, osea no la tengo tan sensible como antes.

Voy a hablar un poco de los efectos secundarios. Labios secos, esto es lo mas denso del tratamiento. Pero con manteca de cacao se arregla. No por esto vamos a impedir que nuestra cara mejore. Sangrado de encias, me sangro un par de veces cuando me estaba lavando los dientes (soy muy brusco jaj). Sangrado de nariz, solo cuando me tocaba, si no, no. Cansancio. si, la verdad que si. Antes aguantaba unos cuantos partiditos de futbol entre amigo, y ahora a los 20 min ya estaba fundido. Con la pastilla tenes que exigirle menos a tu cuerpo. Osea si vas a gimnasio y levantas 100kilos, ahora levanta 70, o hace menos series, o menos exigencia. Pelo seco. SI, y esto esta buenisimo xd, porque te deja un efecto de "pelo limpio" por mas que no te banes jaj. Es mentira que el pelo se te rompe, o no crece mas. Me corte 6 veces el pelo creo de tan largo ¬¬ . Disfuncion erectil. es MENTIRA. Depresion. y. ocurre al momento del primer mes, y no por efecto de la pastilla, si no que ocurre porque uno ve que esta tomando pastilla para mejorar el acne y se levanta al otro dia y le sale grano enorme. pero eso no mas es, y ocurre al primer o segundo mes. Comportamiento violento o la agresion. es MENTIRA, este ultimo tiempo estoy hiper pacifico, no se que paso JAJAJ Psicosis, Ideas suicida, Intentos de suicidio. ideas suicida y eso NADA QUE VER..creo que todo esto esta relacionado con uno mismo. si ves un grano enorme y te queres matar no es cuestion de la pastilla. Ceguera de noche, si un poco me costaba porque se me secaba los ojos, tuve que usar lagrimas artificiales para estudiar o algo que me demande mucho tiempo la vista. use TEARS NATURALE FORTE precio aproximado 80 pesos argentinos. Dificultad auditiva, no para nada. FALSO Eso de que no te deja crecer es mentira! creci 3 cm! Si usas lentes de contactos, simplemente usa lagrimas artificiales. SI SOS MUJER ES OBLIGATORIO LA PASTILLA ANTICONCEPTIVA O NO SE COMO SE LLAMA, EL TEMA ES QUE PARA NADA DEL MUNDO TIENEN QUE QUEDAR EMBARAZADA CON ESTA PASTILLA PORQUE SI NO EL HIJO LES SALE DEFORME O PUEDEN PERDERLO. HABLAR CON LA DERMATOLOGA DE ESTO. Fotosensibilidad, si me paso xd igual es una boludes, es como cuando te despertas y esta la luz prendida, te cuesta un rato acostumbrarte. Debilitamiento de la piel, no es un efecto secundario notable, solo que si sos mujer ni se te ocurra depilarte con cera, al menos que quieras quedarte en carne viva. Dolor muscular, de espalda, si me paso, en especial porque hago tenis y me dolia bastante la espalda. Y otra cosa que te va a ocurrir en invierno. PIEL SECA, si o si cuando te levantes vas a ver toda tu cara seca. pero con un jabon o algo que te de la dermatologa para limpiarte se te sale xd.

Y TODAS LAS OTRAS ENFERMEDADES GROSAS QUE APARECEN, como INFARTO AL CORAZON, PARO CARDIORESPIRATORIO, PANCREATITIS, TUMOR CEREBRAL y todo eso..no a mi no me paso. justamente para eso la medica les hace hacerse analisis, si uno no es apto para este medicamente no se le deja tomar..justamente para evitar esto.

ACLARO ALGO QUE ME PARECE MUY IMPORTANTE. YO EMPECE ESTE MEDICAMENTO EN INVIERNO, ES LO MEJOR QUE PUEDE PASAR EN INVIERNO, YA QUE NO HAY SOL, EN DIAS DE SOL SE TENDRIA QUE USAR UN PROTECTOR. LO EMPECE EN MARZO Y TERMINE EN NOVIEMBRE.

Ahora voy a poner los productos que utilice:

Leche de limpieza descongestiva Dra Norma Bustos. (Pagina para ver sus productos y poder contactarte http://www. formulanormabustos. com. ar )

Simplemente tomaba la pastilla y usaba esta leche descongestiva, NADA MAS. Vi otras personas que usaban hidratante y varias cosas mas. con esta leche de limpieza no necesitas nada mas, solo seria pastilla+leche descongestiva. Con lavarte 1 vez por dia creo que es suficiente. (Habia veces que me lavaba cada 2 dias o cada 3 y no pasa nada, simplemente te hidrata) Esta leche utilice en los 8 meses de tratamiento. Y luego, una vez finalizado el tratamiento, para mantenerme y ademas como venia el calor me dio lo siguiente: Un gel espumante de limpieza. (De la misma Dra Norma Bustos)

Las mantecas de cacao utilizadas fueron:

De esas utilice la azul (muy hidratante) y la amarilla (no me gusto porque era debil y ademas te deja blanco porque tiene protector solar). La que mas me gusto fue

Es hidratante pero no tanto. A mi me gusto, todo depende de los labios de cada uno.

Ya en los dias de Noviembre que hay dias de Sol, utilice este protector: Maprosol 40 Es muy bueno

Y eso no mas..Luego para ahora que es Diciembre y ya es verano y uno quiere tener un colorcito lindo. me dio 2 opciones: O tomo sol pero con un protector llamado Dermaglos FP 20

O me ponia un autobronceante llamado Fotosol Vetra, Autobronceante Emulsion x 100ml. (o algo asi, no entiendo muy bien la letra de doctor xd) O este que es un poco mas caro pero es de linda calidad.

y me dio 3 recomendaciones NUNCA USES ASEPXIA NUNCA USES RAYITO DE SOL NUNCA USES HAWAIIAN TROPIC NUNCA ESCUPAS PARA ARRIBA (na este es joda ) Me dijo que gracias a esos productos comerciales, es que ella tiene gran cantidad de pacientes.

Respecto a mi alimentacion. sinceramente no me cuide nada :s pero todo depende del analisis de cada uno, a mi me dio bastante bien por eso me daba el gusto de comer pizzas, gaseosas y eso, pero repito depende de cada uno. Traten de comer sano siempre, no solo por el acne, si no para estar saludables. Y, NADA pero NADA de cerveza! Ya que te higado esta trabajando bastante con la pastilla, la cerveza lo va a terminar de liquidar, NO TOMEN. El efecto de la pastilla una vez terminado el tratamiento dura aproximadamente 1 mes. Y segun como tomaste, te garantiza desde un par de anos minimo no tener granos, hasta puede ser que nunca mas te vuelvan, que es lo que generalmente ocurre.

En conclusion, la pastilla es muy buena, te deja la cara perfecta! tal como la sonaste. Si los analisis dan bien, no hay impedimentos. Lo que si, lo de los labios secos, y a veces sangrado de nariz (solo si te tocas. me habra pasado 10 veces en 8 meses), dolor muscular, cara seca, si o si te va a pasar. Pero nada mas. Obviamente ASESORENSE con un profesional, y mas si SOS MUJER. (por riesgo al embarazo). Otro punto a destacar es el elevado precio de la pastilla, la caja de 60 pastillas de 20mg cuesta 400 pesos aproximadamente, y con el descuento solidario que te dan los medicos, aproximadamente 300 pesos. YO SOLO LES CUENTO MI EXPERIENCIA, NO SE AUTOMEDIQUEN POR QUE AHI SI CORREN RIESGOS DE LOS EFECTOS SECUNDARIOS MAS GRAVES, CONSULTEN CON UN PROFESIONAL. Cualquier cosa que me acuerde, voy a ir agregando. Preguntenme todo lo que quierannn

p. d: disculpen la mala ortografia, pero en la computadora el hecho de poner acentos, y comas, y mayusculas me enlentece mucho la escritura. Voy a ir arreglando en un ratito los horrores ortograficos

Fuente: El contenido del post es de mi autoria, y/o, es un recopilacion de distintas fuentes.

Hy Zaret, Zaret

Hy Zaret

Artist Biography by Steve Huey

Best known as the co-writer of the perennial "Unchained Melody," lyricist Hy Zaret was born in New York in 1907, and scored his first major success in 1935, when he teamed up with Saul Chaplin and Sammy Cahn to co-write the pop standard "Dedicated to You." The early '40s brought some collaborations with Alex C. Kramer and Joan Whitney. including 1941's "It All Comes Back to Me Now" and the socially conscious, WWII-themed "My Sister and I." Zaret also wrote lyrics for an English translation of the French Resistance song "The Partisan" (aka "The Song of the French Partisan"), which was later covered by Leonard Cohen. Far and away his biggest success, though, was "Unchained Melody," a song he co-wrote with underrated film composer Alex North for the 1955 prison film Unchained (hence the title). No less than three versions of the song -- by Les Baxter. Al Hibbler. and Roy Hamilton -- hit the Top Ten that year, with Hibbler 's version ranking as the best known for the next ten years. The song was also recorded successfully by Jimmy Young and Liberace and covered by countless others, but the Righteous Brothers ' 1965 version -- given a supremely romantic production by Phil Spector -- became the definitive take, reaching the pop Top Five. That recording was revived in 1990 thanks to its inclusion in the film Ghost and nearly reached the Top Ten all over again. Meanwhile, Zaret turned his attention to educational children's music in the late '50s, collaborating with Lou Singer on a six-album series dubbed Singing Science ; different volumes covered space, energy and motion, experiments, weather, and nature. The records were quite successful, and the song "Why Does the Sun Shine?" (aka "The Sun Is a Mass of Incandescent Gas") was even covered by quirky alt-rockers They Might Be Giants in 1994. Zaret died on July 3, 2007, at the age of 99, just over a month short of his 100th birthday.

Supprelin - La (Histrelin Acetate), Supplin

Discover important information you can share with parents and caregivers about CPP and treatment with SUPPRELIN ® LA.

INDICATION

SUPPRELIN ® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP)

Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment

Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia

IMPORTANT SAFETY INFORMATION about SUPPRELIN ® LA

SUPPRELIN ® LA is contraindicated in patients who are hypersensitive to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs and in females who are or may become pregnant while receiving the drug. SUPPRELIN ® LA is pregnancy Category X. SUPPRELIN ® LA may cause fetal harm or spontaneous abortion when administered to pregnant patients. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus

SUPPRELIN ® LA. like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease

Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended to avoid potential complications. Proper surgical technique is critical in minimizing adverse events related to the insertion and the removal of the histrelin implant. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used including ultrasound, CT, or MRI (this implant is not radiopaque). In some cases the implant broke during removal and multiple pieces were recovered. Rare events of spontaneous extrusion have been observed in clinical trials. During SUPPRELIN ® LA treatment, patients should be evaluated for evidence of clinical and biochemical suppression of CPP manifestation

LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should be assessed

In clinical trials, the most common adverse reactions involved the implant site and included discomfort, bruising, soreness, pain, tingling, itching, erythema, and implant area protrusion and swelling

Seizures (Nervous system disorders) have been identified during post-approval use of SUPPRELIN ® LA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure

The safety and effectiveness in pediatric patients under the age of 2 years has not been established. The use of SUPPRELIN ® LA in children under 2 years is not recommended

INDICATION

SUPPRELIN ® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP)

Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment

Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia

IMPORTANT SAFETY INFORMATION about SUPPRELIN ® LA

SUPPRELIN ® LA is contraindicated in patients who are hypersensitive to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs and in females who are or may become pregnant while receiving the drug. SUPPRELIN ® LA is pregnancy Category X. SUPPRELIN ® LA may cause fetal harm or spontaneous abortion when administered to pregnant patients. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus

SUPPRELIN ® LA. like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease

Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended to avoid potential complications. Proper surgical technique is critical in minimizing adverse events related to the insertion and the removal of the histrelin implant. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used including ultrasound, CT, or MRI (this implant is not radiopaque). In some cases the implant broke during removal and multiple pieces were recovered. Rare events of spontaneous extrusion have been observed in clinical trials. During SUPPRELIN ® LA treatment, patients should be evaluated for evidence of clinical and biochemical suppression of CPP manifestation

LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should be assessed

In clinical trials, the most common adverse reactions involved the implant site and included discomfort, bruising, soreness, pain, tingling, itching, erythema, and implant area protrusion and swelling

Seizures (Nervous system disorders) have been identified during post-approval use of SUPPRELIN ® LA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure

The safety and effectiveness in pediatric patients under the age of 2 years has not been established. The use of SUPPRELIN ® LA in children under 2 years is not recommended

Reference

1. SUPPRELIN ® LA [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; 2013.

Intended for U. S. Residents Only

[ 1 2 3 4 5 6 7 8 9 10 14 ]